{"8dbe02cb3a30d532b92762b08c8745b0097b2889": [["Evolution of the \"flatten the curve\"The COVID-19 pandemic has caused unprecedented impacts on the global society, threatening to exhaust the capacity of health care systems and compromising the operations of many economic sectors.", [["the \"flatten the curve", "PROBLEM", 13, 35], ["The COVID", "TEST", 36, 45], ["flatten", "OBSERVATION_MODIFIER", 18, 25], ["unprecedented", "OBSERVATION_MODIFIER", 69, 82], ["impacts", "OBSERVATION_MODIFIER", 83, 90], ["global", "OBSERVATION_MODIFIER", 98, 104], ["society", "OBSERVATION", 105, 112]]], ["The \"flatten the curve\" graph, whose origin can be traced back to the Centers for Disease Control and Prevention (CDC 2007) , has become a popular visualization tool in the midst of COVID-19 pandemic to explain the benefits of containment, suppression, and mitigation measures.", [["Disease Control", "TREATMENT", 82, 97], ["mitigation measures", "TREATMENT", 257, 276]]], ["Since CDC developed the graph, several versions were created such as the use of different color shadings to contrast the epidemic waves associated with different intervention scenarios (see for example, London and Milan 2020) .", [["the graph", "TEST", 20, 29]]], ["Furthermore, in a Twitter post by Harris (2020) , a horizontal line was added to represent the healthcare system capacity, which was featured in a New York Times article (Roberts 2020) .", [["a horizontal line", "TREATMENT", 50, 67]]], ["Animation has also been created to illustrate ways with which the curve can be flattened (Wiles 2020; Stevens 2020 ).Pandemic intervention measuresRecently, the WEIGHT framework (Santos et al. 2020) was conceptualized to explore the multiple dimensions of disasters.", [["Pandemic intervention measures", "TREATMENT", 117, 147], ["flattened", "OBSERVATION_MODIFIER", 79, 88]]], ["Nonetheless, the specific focus of the perspective shall be on the analysis of the economic losses that may arise from pandemic-related workforce absenteeism.", [["the analysis", "TEST", 63, 75], ["the economic losses", "PROBLEM", 79, 98], ["pandemic", "PROBLEM", 119, 127]]], ["Workforce recovery analysis in the context of disaster preparedness deserves an equitable level of importance and emphasis placed on critical infrastructure systems.", [["Workforce recovery analysis", "TEST", 0, 27]]], ["Disaster management often tends to focus more on restoring damaged infrastructure systems to their pre-disaster levels, consequently leaving relatively less attention on managing losses that could stem from workforce disruptions and related factors.", [["Disaster management", "TREATMENT", 0, 19]]], ["The analysis of workforce recovery relative to critical infrastructure protection still remains underdeveloped.", [["workforce recovery", "TREATMENT", 16, 34], ["critical infrastructure protection", "TREATMENT", 47, 81], ["infrastructure protection", "OBSERVATION", 56, 81]]], ["In contrast to the numerous publications on infrastructure systems in the context of disaster risk management, a disproportionately low number of disaster-related research articles focus on the workforce.", [["disaster risk management", "TREATMENT", 85, 109], ["numerous", "OBSERVATION_MODIFIER", 19, 27], ["publications", "OBSERVATION", 28, 40], ["disproportionately", "OBSERVATION_MODIFIER", 113, 131], ["low number", "OBSERVATION_MODIFIER", 132, 142]]], ["1 * Joost Santos joost@gwu.edu 1 George Washington University, Washington, DC, USA Effective pharmaceutical interventions (e.g., vaccines, antivirals) are not immediately available for novel viruses, like the coronavirus associated with COVID-19.", [["DC", "ANATOMY", 75, 77], ["coronavirus", "DISEASE", 209, 220], ["coronavirus", "ORGANISM", 209, 220], ["USA Effective pharmaceutical interventions", "TREATMENT", 79, 121], ["vaccines", "TREATMENT", 129, 137], ["antivirals", "TREATMENT", 139, 149], ["novel viruses", "PROBLEM", 185, 198], ["the coronavirus", "PROBLEM", 205, 220], ["COVID", "TEST", 237, 242]]], ["Hence, health agencies across the globe rely on nonpharmaceutical interventions, or NPIs, to manage the spread of infections.", [["infections", "DISEASE", 114, 124], ["nonpharmaceutical interventions", "TREATMENT", 48, 79], ["NPIs", "TREATMENT", 84, 88], ["infections", "PROBLEM", 114, 124], ["globe", "ANATOMY", 34, 39], ["infections", "OBSERVATION", 114, 124]]], ["Examples of NPIs include hand hygiene, personal protective equipment, social distancing, travel restrictions, and school/ work closures, among others.", [["hand", "ANATOMY", 25, 29], ["hand", "ORGANISM_SUBDIVISION", 25, 29], ["hand hygiene", "TREATMENT", 25, 37]]], ["Several recent articles have distinguished several categories of NPIs: containment, suppression, and mitigation.Pandemic intervention measuresContainment is the approach of managing individual infection chains (e.g., broad testing, contact tracing, isolation of travelers coming from high-prevalence areas, travel restrictions, among others).", [["NPIs", "DISEASE", 65, 69], ["infection", "DISEASE", 193, 202], ["Pandemic intervention measures", "TREATMENT", 112, 142], ["managing individual infection chains", "PROBLEM", 173, 209], ["broad testing", "TEST", 217, 230], ["contact tracing", "TEST", 232, 247], ["travelers", "TREATMENT", 262, 271], ["containment", "OBSERVATION_MODIFIER", 71, 82], ["infection", "OBSERVATION", 193, 202]]], ["Suppression measures are more aggressive and are typically applied at the early onset of the outbreak to keep infections to a minimum (Pueyo 2020) .", [["infections", "DISEASE", 110, 120], ["Suppression measures", "TREATMENT", 0, 20], ["more aggressive", "OBSERVATION_MODIFIER", 25, 40]]], ["Suppression measure include mandated quarantine 2 in addition to implementing some of the containment measures like broad testing and travel restrictions).", [["the containment measures", "TREATMENT", 86, 110], ["broad testing", "TEST", 116, 129]]], ["Furthermore, enforcement of quarantine would consequently lead to suspension of business and school operations, as well as large gatherings, during the pandemic period.", [["quarantine", "TREATMENT", 28, 38], ["large", "OBSERVATION_MODIFIER", 123, 128]]], ["Although both containment and suppression measures can be effective in decreasing the duration of the first wave, the likelihood and severity of a second or subsequent waves can be more extreme in the absence of vaccines, relative to mitigation.", [["vaccines", "TREATMENT", 212, 220], ["both", "OBSERVATION_MODIFIER", 9, 13], ["containment", "OBSERVATION_MODIFIER", 14, 25]]], ["Mitigation measures aim to delay further spread of the disease such as social distancing, personal protective equipment (PPE), and hand hygiene.", [["hand", "ANATOMY", 131, 135], ["hand", "ORGANISM_SUBDIVISION", 131, 135], ["Mitigation measures", "TREATMENT", 0, 19], ["the disease", "PROBLEM", 51, 62], ["disease", "OBSERVATION", 55, 62]]], ["The advantages are that it requires less extreme restriction on contact, and that at the end of mitigation phase enough people would have contracted the virus, developed herd immunity, and are at a low or negligible risk of reinfection.Pandemic intervention measuresSeveral articles have discussed the distinctions in containment, suppression and mitigation measures in terms of their benefits as well as their implementation challenges (see, for examples, Ferguson et al. 2020) .", [["people", "ORGANISM", 120, 126], ["people", "SPECIES", 120, 126], ["the virus", "PROBLEM", 149, 158], ["reinfection", "PROBLEM", 224, 235], ["Pandemic intervention measures", "TREATMENT", 236, 266], ["mitigation measures", "TREATMENT", 347, 366], ["reinfection", "OBSERVATION", 224, 235]]], ["Regardless of whether the implementation of such measures is mandated or advisory, workforce-related disruption is an inevitable outcome of disease outbreaks.", [["such measures", "TREATMENT", 44, 57], ["disease outbreaks", "PROBLEM", 140, 157]]], ["Nonetheless, the phenomenon of \"forced\" workforce absenteeism is unprecedented and is an area that has gained attention due to the COVID-19 pandemic.", [["the COVID", "TEST", 127, 136], ["pandemic", "PROBLEM", 140, 148]]], ["Forced workforce absenteeism is a consequence of regulations such as quarantine, travel bans/ restrictions, and mandated business closures.Epi curves, economic input-output data, and workforce disruptionsHealth agencies publish data on the number of infections on affected regions, which when normalized will create a time series of attack rates as the pandemic progresses from the first documented case to the peak, and until acceptable recovery is reached.", [["infections", "DISEASE", 250, 260], ["Forced workforce absenteeism", "PROBLEM", 0, 28], ["Epi curves", "TEST", 139, 149], ["economic input-output data", "TEST", 151, 177], ["workforce disruptions", "TREATMENT", 183, 204], ["infections on affected regions", "PROBLEM", 250, 280], ["attack rates", "TREATMENT", 333, 345], ["infections", "OBSERVATION", 250, 260]]], ["This is typically referred to as epidemic curve (or epi curve).", [["epidemic curve", "TEST", 33, 47], ["epi curve", "TEST", 52, 61]]], ["An epi curve can be constructed from data published by health agencies and research institutions.", [["An epi curve", "TREATMENT", 0, 12]]], ["3 Typically, the y-axis of an epi curve shows the number of people infected by the disease, while the x-axis depicts the time in days.", [["people", "ORGANISM", 60, 66], ["people", "SPECIES", 60, 66], ["an epi curve", "TEST", 27, 39], ["the disease", "PROBLEM", 79, 90], ["disease", "OBSERVATION", 83, 90]]], ["The daily number of new infections can be expressed in terms of a percentage relative to the population of the affected region.", [["infections", "DISEASE", 24, 34], ["new infections", "PROBLEM", 20, 34], ["daily", "OBSERVATION_MODIFIER", 4, 9], ["number", "OBSERVATION_MODIFIER", 10, 16], ["new", "OBSERVATION_MODIFIER", 20, 23], ["infections", "OBSERVATION", 24, 34], ["affected", "OBSERVATION", 111, 119]]], ["Using the attack rate data in epi curves, it is possible to estimate the resulting disruption to various workforce sectors.", [["the attack rate data", "TEST", 6, 26], ["epi curves", "TREATMENT", 30, 40]]], ["When a production factor is degraded (e.g., workforce disruptions during a pandemic), the output of a dependent economic sector can be estimated.", [["production factor", "PROTEIN", 7, 24], ["the output", "TEST", 86, 96], ["a dependent economic sector", "TREATMENT", 100, 127]]], ["Economic sectors and infrastructure systems depend on their workforce in varying degrees.", [["varying degrees", "OBSERVATION_MODIFIER", 73, 88]]], ["As the level of labor dependence increases for a sector, its expected economic loss is also expected to rise in the event of workforce-debilitating events, like pandemics.", [["labor dependence", "PROBLEM", 16, 32], ["its expected economic loss", "PROBLEM", 57, 83], ["debilitating events", "PROBLEM", 135, 154], ["pandemics", "PROBLEM", 161, 170], ["economic loss", "OBSERVATION", 70, 83]]], ["Some sectors are less labor-intensive than others.", [["less labor", "PROBLEM", 17, 27], ["less", "OBSERVATION_MODIFIER", 17, 21], ["labor", "OBSERVATION", 22, 27], ["intensive", "OBSERVATION_MODIFIER", 28, 37]]], ["A case in point, automation in sectors such as advanced manufacturing has reduced dependence on workforce, which were traditionally labor-intensive.", [["reduced dependence", "PROBLEM", 74, 92], ["traditionally labor", "PROBLEM", 118, 137], ["reduced", "OBSERVATION_MODIFIER", 74, 81], ["dependence", "OBSERVATION_MODIFIER", 82, 92]]], ["Furthermore, it is possible to account for the flexibility of some economic sectors to perform workforce continuity strategies (e.g., teleworking), in which healthy workers in quarantine are assumed to be able to work remotely; hence reducing the impact of business closures.Epi curves, economic input-output data, and workforce disruptionsUsing economic input-output data from national statistical agencies, 5 the efficacy of containment, suppression, and mitigation measures can be compared against a baseline epi curve, where minimal intervention is imposed.", [["workforce continuity strategies", "TREATMENT", 95, 126], ["business closures", "TREATMENT", 257, 274], ["Epi curves", "TEST", 275, 285], ["economic input-output data", "TEST", 287, 313], ["workforce disruptions", "TREATMENT", 319, 340], ["economic input-output data", "TEST", 346, 372], ["mitigation measures", "TREATMENT", 457, 476], ["a baseline epi curve", "TEST", 501, 521], ["minimal intervention", "TREATMENT", 529, 549]]], ["Simulation results indicate that strict suppression measures can significantly flatten the curve (James et al. 2020) .", [["strict suppression measures", "TREATMENT", 33, 60]]], ["In addition to relieving the pressure off the healthcare system, such measures can also decrease the expected economic loss relative to the baseline (Orsi and Santos 2010) .", [["the expected economic loss", "PROBLEM", 97, 123], ["pressure", "OBSERVATION_MODIFIER", 29, 37], ["economic loss", "OBSERVATION", 110, 123]]], ["This result may be counterintuitive at first since suppression measures (e.g., quarantine, travel restrictions, and business closures, among others) arguably generate costly opportunity losses.", [["suppression measures", "TREATMENT", 51, 71]]], ["Nonetheless, the baseline scenario-which assumes significantly fewer closures-may lead to steeper and faster incidences of absenteeism due to more workers getting sick, caring for sick family members, or worse, dying-ultimately creating a surge in economic losses.", [["absenteeism", "PROBLEM", 123, 134]]], ["Consistently, findings from the research work of Sergio Correia et al. (2020) concluded that US cities that implemented more aggressive and prolonged social distancing measures emerged with higher employment growth rates several years after the 1918 Spanish Flu pandemic.", [["Flu", "CHEMICAL", 258, 261], ["prolonged social distancing measures", "TREATMENT", 140, 176]]], ["Nonetheless, an important caveat has to be made with the complexities and uncertainties surrounding COVID-19.", [["COVID-19", "CHEMICAL", 100, 108], ["COVID", "TEST", 100, 105]]], ["To wit, steep escalation of unemployment rates and sector-specific losses are currently being experienced worldwide and there will come a point in time that prolonged implementation of suppression and mitigation measures may result in global economic collapse.", [["suppression and mitigation measures", "TREATMENT", 185, 220], ["global economic collapse", "PROBLEM", 235, 259], ["global", "OBSERVATION_MODIFIER", 235, 241], ["economic", "OBSERVATION_MODIFIER", 242, 250], ["collapse", "OBSERVATION", 251, 259]]], ["Hence, government assistance and creative approaches 6 have to be put in place to cushion the losses to vulnerable sectors such as restaurants, retail stores, personal care services, and entertainment, among others.Epi curves, economic input-output data, and workforce disruptionsRecent articles cautioned that with minimal intervention, COVID-19 will be responsible for mortalities in the magnitude of hundreds of thousands, if not, millions (Pueyo 2020; Yong 2020) .", [["creative approaches", "TREATMENT", 33, 52], ["Epi curves", "TEST", 215, 225], ["economic input-output data", "TEST", 227, 253], ["workforce disruptions", "TREATMENT", 259, 280], ["minimal intervention", "TREATMENT", 316, 336], ["COVID", "TREATMENT", 338, 343]]], ["Hence, expedited production of PPEs, mass testing, enforced social distancing, and clear national/global coordination policies are needed to decrease the magnitude of such dire consequences to a minimum.", [["PPEs", "PROBLEM", 31, 35], ["mass testing", "TEST", 37, 49], ["mass", "OBSERVATION", 37, 41]]], ["A case in point, Yu and Aviso (2020) recently proposed a conceptual multiscale hierarchical framework to better coordinate supply chains at the firm, national, and global levels in the aftermath of disease outbreaks.Epi curves, economic input-output data, and workforce disruptionsWhy then are governments cautious and generally averse with the implementation of containment, suppression, and mitigation measures?", [["disease outbreaks", "PROBLEM", 198, 215], ["Epi curves", "TEST", 216, 226], ["economic input-output data", "TEST", 228, 254], ["workforce disruptions", "TREATMENT", 260, 281], ["suppression", "TREATMENT", 376, 387], ["mitigation measures", "TREATMENT", 393, 412], ["firm", "OBSERVATION_MODIFIER", 144, 148], ["disease", "OBSERVATION", 198, 205]]], ["The main argument is that such measures may impinge on personal liberty.", [["main", "OBSERVATION_MODIFIER", 4, 8], ["argument", "OBSERVATION", 9, 17]]], ["Previous studies (see, for example, Hawkley and Capitanio 2015) have also concluded that social isolation can adversely affect mental health, and can increase the risk of anxiety, depression, and substance use.", [["anxiety", "DISEASE", 171, 178], ["depression", "DISEASE", 180, 190], ["Previous studies", "TEST", 0, 16], ["anxiety", "PROBLEM", 171, 178], ["depression", "PROBLEM", 180, 190]]], ["Alafrangy (2020) , who worked in NASA's Human Exploration Research Analog (HERA) project, relayed his first-hand experience living in a confined environment for 45 days:Epi curves, economic input-output data, and workforce disruptionsThe impact of isolation on humans, which are by nature social beings, can be profound.", [["Human", "ORGANISM", 40, 45], ["humans", "ORGANISM", 261, 267], ["Human", "SPECIES", 40, 45], ["humans", "SPECIES", 261, 267], ["humans", "SPECIES", 261, 267], ["Epi curves", "TREATMENT", 169, 179], ["economic input-output data", "TEST", 181, 207], ["workforce disruptions", "TREATMENT", 213, 234], ["isolation", "OBSERVATION", 248, 257]]], ["My time in HERA allowed me to develop a few techniques to mitigate the effects of isolation, which can be applicable to the current COVID-19 situation.", [["isolation", "TREATMENT", 82, 91]]], ["I learned that following a strict schedule helped me keep busy and remain active.", [["active", "OBSERVATION", 74, 80]]], ["It is not difficult, however, to understand that this isolation affects everyone, and that people may react differently.Epi curves, economic input-output data, and workforce disruptionsIndeed, personal liberty needs to be carefully balanced against the uncertain consequences that may emerge from a pandemic, especially if it is allowed to run its course with minimal intervention.", [["people", "ORGANISM", 91, 97], ["people", "SPECIES", 91, 97], ["Epi curves", "TEST", 120, 130], ["economic input-output data", "TEST", 132, 158], ["workforce disruptions", "TREATMENT", 164, 185], ["minimal intervention", "TREATMENT", 360, 380], ["not difficult", "UNCERTAINTY", 6, 19]]], ["However, containment, suppression, and mitigation measures are not a panacea.", [["containment", "OBSERVATION_MODIFIER", 9, 20]]], ["Hence, vaccines, antivirals, and other pharmaceutical interventions need to be developed at the quickest time possible to thwart the potential resurgence of the virus.", [["vaccines", "TREATMENT", 7, 15], ["antivirals", "TREATMENT", 17, 27], ["other pharmaceutical interventions", "TREATMENT", 33, 67], ["the virus", "PROBLEM", 157, 166]]], ["Furthermore, government officials and policymakers also need to be mindful of other negative side effects of pandemic interventions.", [["pandemic interventions", "TREATMENT", 109, 131]]], ["To wit, enforcement of quarantine may further expose and amplify the inequality across various socioeconomic segments of the population.", [["quarantine", "TREATMENT", 23, 33]]], ["The impact of COVID-19 on lower income groups has been found to be much more profound, further impeding their ability to access basic resources, employment, as well as services such as healthcare and online education, among others.", [["COVID", "TREATMENT", 14, 19]]], ["Studies also have indicated that low-income groups are more susceptible to contracting the disease itself, which further compounds the socioeconomic disparities associated with COVID-19.Epi curves, economic input-output data, and workforce disruptionsIn sum, containment, suppression, and mitigation measures can have a significant impact on the extent to which the curve can be flattened; consequently reducing the impact on the workforce, healthcare systems, and continuity of government, among others.", [["COVID-19", "CHEMICAL", 177, 185], ["Studies", "TEST", 0, 7], ["low-income groups", "PROBLEM", 33, 50], ["the disease itself", "PROBLEM", 87, 105], ["the socioeconomic disparities", "PROBLEM", 131, 160], ["COVID", "TEST", 177, 182], ["Epi curves", "TEST", 186, 196], ["economic input-output data", "TEST", 198, 224], ["workforce disruptions", "TREATMENT", 230, 251], ["mitigation measures", "TREATMENT", 289, 308], ["low", "OBSERVATION_MODIFIER", 33, 36], ["disease", "OBSERVATION", 91, 98], ["containment", "OBSERVATION_MODIFIER", 259, 270], ["significant", "OBSERVATION_MODIFIER", 320, 331], ["flattened", "OBSERVATION", 379, 388]]], ["Indeed, current disaster preparedness and resilience practices need to be reviewed, re-evaluated, and significantly enhanced to minimize the impact of pandemics and other future disasters on all facets of our global society.Epi curves, economic input-output data, and workforce disruptionsFunding Funding was provided by National Science Foundation (Grant No. 1832635) .", [["pandemics", "DISEASE", 151, 160], ["resilience practices", "TREATMENT", 42, 62], ["pandemics", "PROBLEM", 151, 160], ["Epi curves", "TEST", 224, 234], ["economic input-output data", "TEST", 236, 262], ["workforce disruptions", "TREATMENT", 268, 289], ["global", "OBSERVATION_MODIFIER", 209, 215], ["society", "OBSERVATION", 216, 223]]]], "9298ac117464f012abcd5eddee62d97b700ac643": [["Positive or negative results from each assay were determined by the signal to cutoff index based on the respective manufacturers' package inserts.", [["each assay", "TEST", 34, 44], ["cutoff index", "TEST", 78, 90], ["the respective manufacturers' package inserts", "TREATMENT", 100, 145], ["negative", "OBSERVATION", 12, 20]]], ["We compared the results from 88 serum samples, of which 68 were from patients with prior positive SARS-CoV-2 PCR results.", [["serum samples", "ANATOMY", 32, 45], ["serum samples", "ORGANISM_SUBSTANCE", 32, 45], ["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["serum samples", "TEST", 32, 45], ["prior positive SARS", "PROBLEM", 83, 102], ["CoV", "TEST", 103, 106]]], ["Onset of symptoms was determined for 63 out of 68 patients.", [["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58], ["symptoms", "PROBLEM", 9, 17]]], ["The onset of symptoms was > 14 days (mean = 18.8, standard deviation = 6.6) for 30 patients and <14 days for 33 (mean = 5.4, standard deviation = 3.3).", [["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["symptoms", "PROBLEM", 13, 21], ["mean", "TEST", 37, 41], ["standard deviation", "TEST", 50, 68], ["mean", "TEST", 113, 117], ["standard deviation", "TEST", 125, 143]]], ["Negative control samples (n=20) were remnant specimens that had been collected and stored frozen prior to the emergence of COVID-19.", [["samples", "ANATOMY", 17, 24], ["remnant specimens", "ANATOMY", 37, 54], ["remnant specimens", "CANCER", 37, 54], ["remnant specimens", "TEST", 37, 54], ["COVID", "TEST", 123, 128]]]], "PMC7369169": [["IntroductionHoneysuckle flower is a common edible-medicinal food with significant anti-inflammatory efficacy [1].", [["Honeysuckle flower", "ORGANISM", 12, 30], ["IntroductionHoneysuckle flower", "TREATMENT", 0, 30], ["significant anti-inflammatory efficacy", "TREATMENT", 70, 108]]], ["It has even been developed into products, such as Chinese famous tea drink Wang Laoji, Jiaduobao, as well as the distilled liquid of Honeysuckle flower.", [["tea", "ORGANISM_SUBDIVISION", 65, 68], ["flower", "ORGANISM_SUBDIVISION", 145, 151], ["tea", "SPECIES", 65, 68], ["Chinese famous tea drink Wang Laoji", "SPECIES", 50, 85], ["Jiaduobao", "TREATMENT", 87, 96]]], ["The annual sales of Honeysuckle flower productions are among the best in China.", [["flower", "ORGANISM_SUBDIVISION", 32, 38], ["Honeysuckle flower productions", "PROBLEM", 20, 50], ["annual", "OBSERVATION_MODIFIER", 4, 10], ["sales", "OBSERVATION_MODIFIER", 11, 16], ["Honeysuckle flower productions", "OBSERVATION", 20, 50]]], ["For example, Jiaduobao's operating income in 2016 was 24 billion yuan, ranking first in the Chinese herbal tea industry with a market share of 52.6%.", [["herbal tea", "CHEMICAL", 100, 110]]], ["In Japan, the Kobayashi's Qingfei Soup is an edible-medicinal prescription containing Honeysuckle flower.IntroductionEthanol precipitation is a characteristic and significant process of Honeysuckle flower production, which calls for a precise quality control method.", [["Ethanol", "CHEMICAL", 117, 124], ["Ethanol", "CHEMICAL", 117, 124], ["Honeysuckle", "ORGANISM", 86, 97], ["flower", "ORGANISM_SUBDIVISION", 98, 104], ["Ethanol", "SIMPLE_CHEMICAL", 117, 124], ["flower", "ORGANISM_SUBDIVISION", 198, 204], ["the Kobayashi's Qingfei Soup", "TREATMENT", 10, 38], ["IntroductionEthanol precipitation", "TREATMENT", 105, 138], ["Honeysuckle flower production", "PROBLEM", 186, 215], ["Honeysuckle flower", "OBSERVATION", 186, 204]]], ["Off-line quality control methods have hysteresis leading to an insecure and unpredictable production quality [2].", [["Off-line quality control methods", "TREATMENT", 0, 32], ["hysteresis", "PROBLEM", 38, 48], ["an insecure and unpredictable production quality", "PROBLEM", 60, 108]]], ["Currently, NIR spectroscopy is the most commonly used PAT process analyser in pharmaceutical technology because of non-destructive measurements and real-time monitoring in process [4,5].", [["NIR spectroscopy", "TEST", 11, 27], ["non-destructive measurements", "TEST", 115, 143]]], ["It is especially suitable for a complex production, which needs process quality control [6,7].IntroductionWu et al. used NIR spectroscopy to monitor the concentration distribution of amino acids in the hydrolysis of Cornu Bubali [2].", [["amino acids", "CHEMICAL", 183, 194], ["amino acids", "CHEMICAL", 183, 194], ["amino acids", "AMINO_ACID", 183, 194], ["NIR spectroscopy", "TEST", 121, 137], ["amino acids", "PROBLEM", 183, 194], ["amino acids", "OBSERVATION", 183, 194]]], ["Xu et al. proposed a multi-phase and multivariate statistical process control strategy for alcohol precipitation of Honeysuckle flower.", [["alcohol", "CHEMICAL", 91, 98], ["alcohol", "CHEMICAL", 91, 98], ["alcohol", "SIMPLE_CHEMICAL", 91, 98], ["flower", "ORGANISM_SUBDIVISION", 128, 134], ["a multi-phase", "TREATMENT", 19, 32], ["multivariate statistical process control strategy", "TREATMENT", 37, 86], ["Honeysuckle flower", "PROBLEM", 116, 134], ["Honeysuckle flower", "OBSERVATION", 116, 134]]], ["Laub-Ekgreen et al. applied NIR spectroscopy to rapid and non-destructive salt concentration monitoring in the pickling process of squid [9].", [["salt", "CHEMICAL", 74, 78], ["salt", "SIMPLE_CHEMICAL", 74, 78], ["Laub", "TEST", 0, 4], ["NIR spectroscopy", "TEST", 28, 44], ["non-destructive salt concentration monitoring", "TREATMENT", 58, 103]]], ["Oxidative damage of pork myofibrils during frozen storage has been monitored by the NIR hyperspectral imaging [10].IntroductionIn the application of NIR to process quality control, there is an essential factor, quantitative model.", [["pork myofibrils", "ANATOMY", 20, 35], ["pork myofibrils", "ORGANISM_SUBSTANCE", 20, 35], ["pork", "SPECIES", 20, 24], ["Oxidative damage of pork myofibrils", "PROBLEM", 0, 35], ["frozen storage", "TREATMENT", 43, 57], ["the NIR hyperspectral imaging", "TEST", 80, 109], ["NIR to process quality control", "TREATMENT", 149, 179]]], ["To establish an accurate NIR model, the most important part is the optimization of the critical modeling parameters (CMPs).", [["an accurate NIR model", "TREATMENT", 13, 34]]], ["One CMP in NIR modeling is the spectral preprocessing because of some interfering information [11].", [["One CMP in NIR modeling", "PROBLEM", 0, 23], ["the spectral preprocessing", "TREATMENT", 27, 53]]], ["Pizarro et al. and Christensen et al. both demonstrated the performance of quantitative NIR models established by different pre-processing methods were diverse [12,13].", [["Pizarro", "TREATMENT", 0, 7], ["quantitative NIR models", "TREATMENT", 75, 98]]], ["Bi et al. proved that, compared with the full spectra, the NIR model established by optimal spectra achieved better performance [15].", [["the NIR model", "TREATMENT", 55, 68]]], ["Yuan et al. indicated that the discriminant models were improved and simplified significantly by variable selection [16].", [["improved", "OBSERVATION_MODIFIER", 56, 64]]], ["In addition, a suitable latent factor is also a CMP to avoid over-fitting and under-fitting for modeling [17].IntroductionIn classical modeling, the CMPs were optimized step-by-step.", [["CMPs", "SIMPLE_CHEMICAL", 149, 153], ["latent factor", "PROTEIN", 24, 37], ["CMPs", "DNA", 149, 153], ["a suitable latent factor", "PROBLEM", 13, 37], ["a CMP", "TREATMENT", 46, 51], ["the CMPs", "TEST", 145, 153]]], ["Genetic algorithm is a commonly used method to optimize the spectral pre-processing method or variable selection method [18].", [["Genetic algorithm", "TEST", 0, 17]]], ["Rosas et al. compared three spectral pre-processing methods for NIR process optimization of a multicomponent formulation [19].", [["a multicomponent formulation", "TREATMENT", 92, 120]]], ["Wu et al. used a novel method to optimize the model performance of Partial least square (PLS), interval PLS (iPLS), backward interval PLS (BiPLS) and moving window PLS (MWPLS), and point out that with different evaluation indicator, the optimal method is diverse [20].", [["a novel method", "TREATMENT", 15, 29], ["interval PLS (iPLS)", "TEST", 95, 114], ["backward interval PLS (BiPLS)", "TREATMENT", 116, 145], ["different evaluation", "TEST", 201, 221]]], ["Pan et al. found that BiPLS was the appropriate variable selection method for establishing the particle size model rather than synergy iPLS (SiPLS) [21].IntroductionNevertheless, the established models optimized step-by-step ignored the interaction among modeling parameters and were not the best in overall situation.", [["BiPLS", "CHEMICAL", 22, 27], ["BiPLS", "SIMPLE_CHEMICAL", 22, 27], ["the particle size model", "TREATMENT", 91, 114], ["particle size", "OBSERVATION_MODIFIER", 95, 108]]], ["An integrated approach was introduced to optimize several modeling parameters simultaneously based on genetic algorithm [22,23].", [["An integrated approach", "TREATMENT", 0, 22], ["genetic algorithm", "TEST", 102, 119]]], ["Similarly, a systematic modeling method was put up by using a processing trajectory to select modeling parameters [[24], [25], [26]].", [["a systematic modeling method", "TREATMENT", 11, 39], ["a processing trajectory", "TREATMENT", 60, 83]]], ["In the ICH Q8 guideline, QbD is defined as a systematic approach to development that begins with predefined objectives and emphasizes product and process understanding, as well as process control, based on sound science and quality risk management [28].", [["ICH", "DISEASE", 7, 10], ["a systematic approach", "TREATMENT", 43, 64]]], ["Dai et al. applied it to the development of a novel RP-HPLC analytical method for Huanglian [31].", [["a novel RP", "TREATMENT", 44, 54]]], ["Similarly, it could also be applied to optimize NIR CMPs by a design of modeling evaluation procedures.IntroductionHowever, the chemometrics variable selection could not discern special components in samples directly.", [["samples", "ANATOMY", 200, 207], ["NIR CMPs", "TREATMENT", 48, 56], ["modeling evaluation procedures", "TEST", 72, 102], ["the chemometrics", "TEST", 124, 140]]], ["Lee et al. argued that the different variable selection methods performed wide variability in their capabilities to identify the consistent subset of variables [32].", [["the different variable selection methods", "TREATMENT", 23, 63]]], ["Du et al. also demonstrated that different chemometrics selection methods led to distinct characteristic wavelengths and bands [33].", [["bands", "TEST", 121, 126]]], ["NIR spectral assignment based on the interrelation between spectra and structure is efficacious to improve model performance and interpretation [34,35].", [["NIR spectral assignment", "TEST", 0, 23]]], ["Chlorogenic acid is the main medicinal component of honeysuckle [36,37].", [["Chlorogenic acid", "CHEMICAL", 0, 16], ["Chlorogenic acid", "CHEMICAL", 0, 16], ["Chlorogenic acid", "SIMPLE_CHEMICAL", 0, 16], ["Chlorogenic acid", "TEST", 0, 16], ["main", "OBSERVATION_MODIFIER", 24, 28], ["medicinal", "OBSERVATION_MODIFIER", 29, 38], ["component", "OBSERVATION_MODIFIER", 39, 48]]], ["It is also used as the quality control component of honeysuckle in Chinese Pharmacopeia.", [["honeysuckle in Chinese Pharmacopeia", "PROBLEM", 52, 87]]], ["Many researches proved that it played an important role in the treatment of SARS virus in 2003 and novel coronavirus pneumonia in 2019.IntroductionTherefore, a design of NIR modeling evaluation procedures was implemented by D-optimal design method according to QbD concept.", [["SARS", "DISEASE", 76, 80], ["coronavirus pneumonia", "DISEASE", 105, 126], ["SARS virus", "SPECIES", 76, 86], ["SARS virus", "PROBLEM", 76, 86], ["novel coronavirus pneumonia", "PROBLEM", 99, 126], ["NIR modeling evaluation procedures", "TEST", 170, 204], ["coronavirus", "OBSERVATION_MODIFIER", 105, 116], ["pneumonia", "OBSERVATION", 117, 126]]], ["Furthermore, getting the characteristic band of chlorogenic acid [38], the special component of Honeysuckle flower, by spectral assignment, this paper creatively combined this characteristic band with modeling CMPs designed by D-optimal to establish a more precise and reliable model.", [["chlorogenic acid", "CHEMICAL", 48, 64], ["chlorogenic acid", "CHEMICAL", 48, 64], ["chlorogenic acid", "SIMPLE_CHEMICAL", 48, 64], ["chlorogenic acid", "TEST", 48, 64], ["Honeysuckle flower", "PROBLEM", 96, 114], ["modeling CMPs", "TEST", 201, 214], ["Honeysuckle flower", "OBSERVATION", 96, 114]]], ["These also provided a reference method for modeling design and the establishment of global optimal models in PAT of edible-medicinal food.On-line NIR spectra acquisition and HPLC analysis in ethanol precipitation process of Honeysuckle flower ::: Materials and methodsHoneysuckle flower was purchased from Ben Cao Fang Yuan Medicine Co. LTD.", [["ethanol", "CHEMICAL", 191, 198], ["ethanol", "CHEMICAL", 191, 198], ["ethanol", "SIMPLE_CHEMICAL", 191, 198], ["spectra acquisition", "TEST", 150, 169], ["HPLC analysis", "TEST", 174, 187]]], ["Its authenticity was determined by Professor Chunsheng Liu of Beijing University of Chinese Medicine.", [["Chinese Medicine", "TREATMENT", 84, 100]]], ["Chlorogenic acid reference standard (lot number: 110777-201005) was supplied by the National Institutes for Food and Drug Control (Beijing, China).", [["Chlorogenic acid", "CHEMICAL", 0, 16], ["110777-201005", "CHEMICAL", 49, 62], ["Chlorogenic acid", "CHEMICAL", 0, 16], ["Chlorogenic acid", "SIMPLE_CHEMICAL", 0, 16]]], ["HPLC grade acetonitrile was purchased from Tedia (USA).", [["acetonitrile", "CHEMICAL", 11, 23], ["acetonitrile", "CHEMICAL", 11, 23], ["acetonitrile", "SIMPLE_CHEMICAL", 11, 23], ["HPLC grade acetonitrile", "PROBLEM", 0, 23], ["acetonitrile", "OBSERVATION", 11, 23]]], ["Deionized water was purified by Milli-Q water system (Millipore Corp., Bedford, MA, USA).On-line NIR spectra acquisition and HPLC analysis in ethanol precipitation process of Honeysuckle flower ::: Materials and methodsThe ethanol precipitation process of Honeysuckle flower was implemented according to a specific production process parameters of a certain enterprise, which was performed in a 3 L glass reactor using an agitator at constant speed of 500 rpm.", [["ethanol", "CHEMICAL", 142, 149], ["ethanol", "CHEMICAL", 223, 230], ["ethanol", "CHEMICAL", 142, 149], ["ethanol", "CHEMICAL", 223, 230], ["ethanol", "SIMPLE_CHEMICAL", 142, 149], ["ethanol", "SIMPLE_CHEMICAL", 223, 230], ["Honeysuckle", "ORGANISM", 256, 267], ["flower", "ORGANISM_SUBDIVISION", 268, 274], ["Deionized water", "TREATMENT", 0, 15], ["spectra acquisition", "TEST", 101, 120], ["HPLC analysis", "TEST", 125, 138], ["The ethanol precipitation", "TREATMENT", 219, 244], ["Honeysuckle flower", "PROBLEM", 256, 274], ["a 3 L glass reactor", "TREATMENT", 393, 412], ["Honeysuckle flower", "OBSERVATION", 256, 274]]], ["Ethanol was pumped into the reactor from the ethanol tank with a flow rate of 75 mL/min.", [["Ethanol", "CHEMICAL", 0, 7], ["ethanol", "CHEMICAL", 45, 52], ["Ethanol", "CHEMICAL", 0, 7], ["ethanol", "CHEMICAL", 45, 52], ["Ethanol", "SIMPLE_CHEMICAL", 0, 7], ["ethanol", "SIMPLE_CHEMICAL", 45, 52], ["Ethanol", "TREATMENT", 0, 7], ["a flow rate", "TREATMENT", 63, 74]]], ["Samples were collected during the alcohol precipitation process at 5 min intervals.", [["Samples", "ANATOMY", 0, 7], ["alcohol", "CHEMICAL", 34, 41], ["alcohol", "CHEMICAL", 34, 41], ["alcohol", "SIMPLE_CHEMICAL", 34, 41], ["Samples", "TEST", 0, 7], ["the alcohol precipitation process", "TREATMENT", 30, 63]]], ["60 samples were collected in this research.", [["samples", "ANATOMY", 3, 10], ["samples", "CANCER", 3, 10]]], ["Sample of 1.5 mL was drawn by a pipette gun each time.", [["Sample", "TEST", 0, 6]]], ["The NIR spectrum was recorded immediately after the sample collection had been completed, which was to ensure that the collected spectrum was consistent with the obtained sample.", [["sample", "ANATOMY", 52, 58], ["the sample collection", "TEST", 48, 69], ["consistent with", "UNCERTAINTY", 142, 157]]], ["The on-line NIR spectra of this alcohol precipitation were collected by the transmission way for 16 times of each sample, setting resolving power as 2500 \u03bcm and scanning range as 1.0 \u03bcm - 2.5 \u03bcm.On-line NIR spectra acquisition and HPLC analysis in ethanol precipitation process of Honeysuckle flower ::: Materials and methodsQuantitative determination by high performance liquid chromatography (HPLC) of chlorogenic acid in Honeysuckle flower was implemented immediately after online NIR sensor measurement.", [["sample", "ANATOMY", 114, 120], ["alcohol", "CHEMICAL", 32, 39], ["ethanol", "CHEMICAL", 248, 255], ["chlorogenic acid", "CHEMICAL", 404, 420], ["alcohol", "CHEMICAL", 32, 39], ["ethanol", "CHEMICAL", 248, 255], ["chlorogenic acid", "CHEMICAL", 404, 420], ["alcohol", "SIMPLE_CHEMICAL", 32, 39], ["ethanol", "SIMPLE_CHEMICAL", 248, 255], ["chlorogenic acid", "SIMPLE_CHEMICAL", 404, 420], ["Honeysuckle", "ORGANISM", 424, 435], ["flower", "ORGANISM_SUBDIVISION", 436, 442], ["this alcohol precipitation", "TREATMENT", 27, 53], ["scanning range", "TEST", 161, 175], ["spectra acquisition", "TEST", 207, 226], ["HPLC analysis", "TEST", 231, 244], ["Quantitative determination", "TEST", 325, 351], ["high performance liquid chromatography", "TEST", 355, 393], ["HPLC", "TEST", 395, 399], ["chlorogenic acid in Honeysuckle flower", "TREATMENT", 404, 442], ["online NIR sensor measurement", "TEST", 477, 506]]], ["A Waters 2695 HPLC system was used with an auto-sampler, a column temperature controller, and a diode-array detector (DAD) (SHIMADZU Corporation, Japan).", [["A Waters 2695 HPLC system", "TREATMENT", 0, 25], ["an auto-sampler", "TREATMENT", 40, 55], ["a column temperature controller", "TREATMENT", 57, 88], ["a diode-array detector", "TREATMENT", 94, 116]]], ["Samples were separated on a Diamonsil C18 column (250 mm \u00d7 4.6 mm; 5 \u03bcm particles; Dikma) using acetonitrile and water containing 0.4% phosphoric acid (13: 87, v/v) as the mobile phase.", [["Samples", "ANATOMY", 0, 7], ["acetonitrile", "CHEMICAL", 96, 108], ["phosphoric acid", "CHEMICAL", 135, 150], ["acetonitrile", "CHEMICAL", 96, 108], ["phosphoric acid", "CHEMICAL", 135, 150], ["acetonitrile", "SIMPLE_CHEMICAL", 96, 108], ["water", "SIMPLE_CHEMICAL", 113, 118], ["phosphoric acid", "SIMPLE_CHEMICAL", 135, 150], ["Samples", "TEST", 0, 7], ["a Diamonsil C18 column", "TREATMENT", 26, 48], ["5 \u03bcm particles", "TREATMENT", 67, 81], ["acetonitrile", "TREATMENT", 96, 108], ["water", "TREATMENT", 113, 118], ["phosphoric acid", "TEST", 135, 150]]], ["The separation parameters have been set, column temperature as 30 \u00b0C; detection wavelength as 327 nm; flow rate as 1.0 mL/min; sample size as 10 \u03bcL.The parameters of D-optimal design for modeling design ::: Materials and methodsThe spectral pre-processing methods, variable selection methods, latent factors of variable selection, and latent factors of PLS model were determined as the CMPs of for D-optimal design.", [["sample", "ANATOMY", 127, 133], ["latent factors", "PROTEIN", 293, 307], ["latent factors", "PROTEIN", 335, 349], ["The separation parameters", "TEST", 0, 25], ["column temperature", "TEST", 41, 59], ["flow rate", "TEST", 102, 111], ["sample size", "TEST", 127, 138], ["The spectral pre-processing methods", "TEST", 228, 263], ["variable selection", "TREATMENT", 311, 329], ["PLS model", "TEST", 353, 362]]], ["Spectral pre-processing method was taken as a categorical variable, including raw, standard normal variate (SNV), Savitzky-Golay smoothing with 9 points (SG9), SG9 combined with first derivative spectra (SG9 + 1D), and SG9 combined with second derivative spectra (SG9 + 2D).", [["Spectral pre-processing method", "TEST", 0, 30], ["Savitzky", "TEST", 114, 122], ["SG9", "TEST", 154, 157], ["SG9", "TEST", 160, 163], ["first derivative spectra (SG9 + 1D)", "PROBLEM", 178, 213], ["SG9", "TEST", 219, 222], ["second derivative spectra", "TEST", 237, 262]]], ["Similarly, variable selection method contains of variable importance in projection (VIP), uninformative variable elimination (UVE), selection ratio (SR), moving window partial least square (MWPLS), and competitive adaptive reweighted sampling (CARS).", [["uninformative variable elimination", "PROBLEM", 90, 124], ["selection ratio", "TEST", 132, 147], ["variable", "OBSERVATION_MODIFIER", 11, 19], ["selection", "OBSERVATION", 20, 29], ["variable", "OBSERVATION_MODIFIER", 49, 57]]], ["Moreover, In order to avoid over-fitting effect and under-fitting effect, latent factors of variable selection and latent factors of PLS were both set as the numerical discrete variable including five levels from 3 to 11.The parameters of D-optimal design for modeling design ::: Materials and methodsFor the optimization of NIR model, the CQAs were determined as coefficient of determination of prediction set (Rpre2) and root mean square error of prediction (RMSEP).", [["CQAs", "SIMPLE_CHEMICAL", 340, 344], ["latent factors", "PROTEIN", 74, 88], ["latent factors", "PROTEIN", 115, 129], ["variable selection", "PROBLEM", 92, 110], ["latent factors of PLS", "PROBLEM", 115, 136], ["NIR model", "TEST", 325, 334]]], ["In practical applications, the lower the RMSEP value, the more robust and accurate the models will be, while Rpre2 is opposite of RMSEP.(1)Rpre2=1\u2212\u2211i=1Nyi\u2212yi2Nwhere, N is the number of validation set, yi represents the reference value of the sample i, yi^ represents the prediction value of the sample i, and yi\u00af is the mean of the reference value of the validation set.The implement of D-optimal design for modeling design ::: Materials and methodsKennard-stone (K-S) (PCA-Score) method was used to divide the sample set into a calibration set and validation set with a ratio as 4:1.", [["Rpre2", "PROTEIN", 109, 114], ["RMSEP", "PROTEIN", 130, 135], ["the lower the RMSEP value", "TEST", 27, 52], ["Materials", "TEST", 428, 437], ["methods", "TEST", 442, 449], ["a ratio", "TEST", 569, 576], ["stone", "OBSERVATION", 457, 462]]], ["Each factor contains five levels.", [["five", "OBSERVATION_MODIFIER", 21, 25], ["levels", "OBSERVATION_MODIFIER", 26, 32]]], ["Setting blocks as 1, 56 total runs have been established and composed of 46 required model points, 5 lack-of-fit points, and 5 replicate points.The implement of D-optimal design for modeling design ::: Materials and methodsIn this research, D-optimal design in this research contains four factors, two nominal factors and two discrete factors.", [["total runs", "TEST", 24, 34]]], ["Each factor contains five levels.The implement of D-optimal design for modeling design ::: Materials and methodsTwo discrete variables were taken as examples to explain the D-optimal algorithm.A.Latent factors of variable selection, 3 to 11.B.Latent factors of PLS model, 3 to 11.", [["Latent factors", "PROTEIN", 195, 209], ["11.B", "PROTEIN", 238, 242], ["Latent factors", "PROTEIN", 243, 257], ["the D-optimal algorithm", "TEST", 169, 192], ["variable selection", "TEST", 213, 231], ["PLS model", "TEST", 261, 270], ["five", "OBSERVATION_MODIFIER", 21, 25], ["levels", "OBSERVATION_MODIFIER", 26, 32], ["variable", "OBSERVATION_MODIFIER", 213, 221], ["selection", "OBSERVATION", 222, 231]]]], "ad9d4ff263446de5e67d88fb61f7266b5099c3ec": [["The recent global impact of COVID-19 has been unprecedented and a parallel battle has also been fought by increasing numbers of nurses for their workplace mental health.", [["COVID-19", "CHEMICAL", 28, 36], ["COVID", "TEST", 28, 33], ["global", "OBSERVATION_MODIFIER", 11, 17], ["impact", "OBSERVATION_MODIFIER", 18, 24]]], ["Factors associated with nurses mental stress and consequence of suicide were identified from a retrospective analysis of six non-representative media case-reports in high and low resource countries.", [["nurses mental stress", "PROBLEM", 24, 44], ["a retrospective analysis", "TEST", 93, 117]]], ["The need for a structured model of nursing workforce mental health preparation, monitoring, support and health care is essential to inform advocacy and timely intervention in pandemic response.Dear Editor,The recent global pandemic of coronavirus disease 2019 (COVID-19) has realized emergent and urgent health care crises for more than 200 countries (Dong et al., 2020) .", [["coronavirus disease", "DISEASE", 235, 254], ["COVID-19", "CHEMICAL", 261, 269], ["coronavirus", "ORGANISM", 235, 246], ["coronavirus disease", "PROBLEM", 235, 254], ["COVID", "TEST", 261, 266], ["coronavirus disease", "OBSERVATION", 235, 254]]], ["The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected more than 9.96 million people (World Health Organization, 2020).", [["acute respiratory syndrome coronavirus", "DISEASE", 11, 49], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 4, 51], ["SARS-CoV-2", "ORGANISM", 53, 63], ["people", "ORGANISM", 101, 107], ["people", "SPECIES", 101, 107], ["severe acute respiratory syndrome coronavirus", "SPECIES", 4, 49], ["SARS-CoV-2", "SPECIES", 53, 63], ["The severe acute respiratory syndrome coronavirus", "PROBLEM", 0, 49], ["SARS-CoV", "TEST", 53, 61], ["severe", "OBSERVATION_MODIFIER", 4, 10], ["acute", "OBSERVATION_MODIFIER", 11, 16], ["respiratory syndrome", "OBSERVATION", 17, 37]]], ["Neither vaccine nor treatments are currently available although guidelines and preventive transmission methods have been identified.", [["treatments", "TREATMENT", 20, 30], ["preventive transmission methods", "TREATMENT", 79, 110]]], ["Scientists worldwide strive to control the exponential growth of SARS-CoV-2 viral infection.", [["SARS", "DISEASE", 65, 69], ["viral infection", "DISEASE", 76, 91], ["SARS-CoV-2 viral", "ORGANISM", 65, 81], ["CoV-", "SPECIES", 70, 74], ["SARS-CoV-2", "SPECIES", 65, 75], ["SARS", "PROBLEM", 65, 69], ["CoV", "PROBLEM", 70, 73], ["2 viral infection", "PROBLEM", 74, 91], ["viral infection", "OBSERVATION", 76, 91]]], ["There are reports that approximately 90,000 healthcare workers have been infected and more than 260 nurses have died of SARS-CoV-2 infections.", [["SARS-CoV-2 infections", "DISEASE", 120, 141], ["SARS-CoV-2", "ORGANISM", 120, 130], ["SARS-CoV", "SPECIES", 120, 128], ["SARS", "PROBLEM", 120, 124], ["CoV", "PROBLEM", 125, 128], ["2 infections", "PROBLEM", 129, 141]]], ["Repeated exposure to alarming reports of COVID-19 and crises among health care facilities can increase stress and for some nurses this has ultimately lead to suicide (Garfin et al., 2020) .Dear Editor,The aim of this study is timely investigation of factors associated with COVID-19 related suicide among hospital nurses from case study evidence of worldwide media reports.", [["COVID-19", "CHEMICAL", 41, 49], ["COVID", "TEST", 41, 46], ["this study", "TEST", 212, 222]]], ["Factors associated with nurses' mental stress and consequences of suicide were identified from a retrospective analysis of six non-representative media case-reports in high and low resource countries from March to June 2020.", [["a retrospective analysis", "TEST", 95, 119]]], ["A 49 year old nurse (S.L.) had volunteered to work with patients on the newly converted COVID-19 ward at Jesolo Hospital.", [["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64]]], ["A few days before her death, she was suffering from fever and took a test for COVID-19.", [["death", "DISEASE", 22, 27], ["fever", "DISEASE", 52, 57], ["fever", "PROBLEM", 52, 57], ["a test", "TEST", 67, 73], ["COVID", "TEST", 78, 83], ["fever", "OBSERVATION", 52, 57]]], ["She lived alone and was waiting there for her test result.", [["her test result", "TEST", 42, 57]]], ["Suddenly, news spread over Venice that a nurse had jumped into the river due to fear of SARS-CoV-2 virus infection.", [["SARS", "DISEASE", 88, 92], ["infection", "DISEASE", 105, 114], ["SARS-CoV-2 virus", "ORGANISM", 88, 104], ["CoV-2 virus", "SPECIES", 93, 104], ["SARS-CoV-2 virus", "SPECIES", 88, 104], ["SARS", "PROBLEM", 88, 92], ["CoV-2 virus infection", "PROBLEM", 93, 114], ["SARS", "OBSERVATION", 88, 92]]], ["At King's College Hospital London on 23rd March, an unnamed nurse in her 20\u2032s was found unresponsive in the Intensive Care Unit, and could not be saved.", [["unresponsive", "PROBLEM", 88, 100]]], ["There had been eight patients die recently in the unit from COVID-19, there was a critical shortage of intensive care beds and half the population of the United Kingdom had already been infected.", [["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["intensive care beds", "TREATMENT", 103, 122], ["infected", "OBSERVATION", 186, 194]]], ["Nurses and doctors were working at risk without the personal protective equipment recommended by the World Health Organization.Dear Editor,The third case was in Italy, also sourced at Daily Mail News the following day (26th March 2020).", [["the personal protective equipment", "TREATMENT", 48, 81]]], ["After being confirmed positive for COVID-19 on 10th March (2020), the National Federation of Italian Nurses expressed \"pain and dismay\" at her passing.Dear Editor,The fourth case was in the USA, sourced at Guardian News (20th May 2020).", [["pain", "DISEASE", 119, 123], ["COVID", "TEST", 35, 40], ["pain", "PROBLEM", 119, 123]]], ["A 32 year old male nurse, William Coddington from South Florida took his own life following an overdose.", [["overdose", "DISEASE", 95, 103], ["an overdose", "PROBLEM", 92, 103]]], ["He was concerned about rationing N95 masks to one per shift, a shortage of gowns, and the face masks were snapping.", [["rationing N95 masks", "TREATMENT", 23, 42], ["gowns", "TREATMENT", 75, 80], ["the face masks", "TREATMENT", 86, 100], ["snapping", "PROBLEM", 106, 114], ["snapping", "OBSERVATION", 106, 114]]], ["He had volunteered to work in the JFK Corona virus unit because he felt he was needed at the front-line but was becoming increasingly fearful and traumatized.", [["He", "ORGANISM", 0, 2], ["increasingly fearful", "PROBLEM", 121, 141], ["traumatized", "PROBLEM", 146, 157]]], ["He was starting to struggle with isolation and an opioid addiction and supported only by virtual support meetings.", [["isolation", "TREATMENT", 33, 42], ["an opioid addiction", "TREATMENT", 47, 66]]], ["The day before he died, one fell off while he was intubating a patient and he felt 'things' splash on his face.Dear Editor,The fifth case, in Mexico, sourced by Yahoo News Australia (4th June 2020) involved Maria del Carmen Galeana.", [["patient", "ORGANISM", 63, 70], ["patient", "SPECIES", 63, 70], ["intubating", "TREATMENT", 50, 60]]], ["This followed her complaint about a shortage of personal protective equipment and other medical equipment and she had tested positive for COVID-19.Dear Editor,The sixth case, in India was by Malayala Maworoma News (English) (2nd June 2020).", [["personal protective equipment", "TREATMENT", 48, 77], ["COVID", "TEST", 138, 143]]], ["COVID-19 has placed immense pressure on health systems across the globe, particularly on critical care services (Schwerdtle et al., 2020) .", [["COVID-19", "CHEMICAL", 0, 8], ["COVID", "TEST", 0, 5], ["pressure", "OBSERVATION_MODIFIER", 28, 36], ["globe", "ANATOMY", 66, 71]]], ["While there is still much to understand about COVID-19, nurses in this case study know that they are at high risk of person-to-person transmission (Jackson et al., 2020) and may pass it on to their families.", [["person", "SPECIES", 117, 123], ["person", "SPECIES", 127, 133]]], ["The mental stress of the potential for contagion, due to inadequate PPE is undoubtedly very high and complicated for some by workplace quarantine, thus placing nurses in positions of high vulnerability.", [["inadequate PPE", "PROBLEM", 57, 71], ["high vulnerability", "PROBLEM", 183, 201], ["high vulnerability", "OBSERVATION", 183, 201]]], ["The burden of COVID-19 has resulted in failure of essential management systems that have resulted in devastating outcomes extending far beyond the COVID-19 disease related statistics (Schwerdtle et al., 2020) to culminate in harm to the nursing workforce through stress and suicide.", [["COVID-19", "CHEMICAL", 14, 22], ["COVID-19", "CHEMICAL", 14, 22], ["COVID", "TEST", 14, 19], ["failure of essential management systems", "PROBLEM", 39, 78], ["devastating outcomes", "PROBLEM", 101, 121], ["failure", "OBSERVATION", 39, 46], ["devastating", "OBSERVATION_MODIFIER", 101, 112]]], ["There is a clear need for a structured model of nursing workforce mental health preparation, monitoring, support and health care, to inform advocacy and timely intervention in pandemic response.Dear Editor,In conclusion, health service managers are best placed to promote new models of care for staff which already work closely in effective teams, and can be fully supported in their roles and more readily identify stress among their peers.", [["clear", "OBSERVATION", 11, 16]]], ["A fully structured and integrated model of nursing workforce mental health preparation and support for their role is recommended, including monitoring, support and health evaluation to maintain a healthy and productive workforce with full partnership in the multidisciplinary team.", [["health evaluation", "TEST", 164, 181]]], ["Further, adequate quantity and quality supplies of PPE, COVID-19 compliant work practices and infection control measures are required to harmonize and reduce the burden of further stress and suicidal ideation.Author contribution statementBoth authors designed the study, collected the data, managed the literature searches and analyzed the data.", [["infection", "DISEASE", 94, 103], ["suicidal ideation", "DISEASE", 191, 208], ["PPE", "PROBLEM", 51, 54], ["COVID-19 compliant work practices", "TREATMENT", 56, 89], ["infection control measures", "TREATMENT", 94, 120], ["further stress", "PROBLEM", 172, 186], ["suicidal ideation", "PROBLEM", 191, 208], ["the study", "TEST", 260, 269], ["the data", "TEST", 336, 344], ["adequate", "OBSERVATION_MODIFIER", 9, 17], ["quantity", "OBSERVATION_MODIFIER", 18, 26]]], ["All authors declare that there are no actual or potential conflicts of interest including any financial, personal or other relationships with other people.", [["people", "ORGANISM", 148, 154], ["people", "SPECIES", 148, 154], ["no", "UNCERTAINTY", 35, 37]]]], "d9021215ff4578102af74b5e90c7c5764ca4844f": [["HIGHLIGHTS:\uf0b7 Lung cancer is a potential risk factor that may increase the rate of Covid-19 related complications. \uf0b7 Elderly lung cancer patients are more likely to have Covid-19 related complications. \uf0b7 Combined treatment with hydroxychloroquine and azithromycin seems a good option in lung cancer patients with Covid-19 diagnosis. \uf0b7 Our efforts should be made to reduce visits to the hospital during the pandemic.Manuscript: 1076 words (without tables and references)Abstract: 296 wordsBackground:Currently there are no reported series determining the Covid-19 infected lung cancer patient\u00b4s characteristics and outcome that allow us to clarify strategies to protect our patients.", [["Lung cancer", "ANATOMY", 13, 24], ["lung cancer", "ANATOMY", 124, 135], ["lung cancer", "ANATOMY", 286, 297], ["lung cancer", "ANATOMY", 571, 582], ["Lung cancer", "DISEASE", 13, 24], ["lung cancer", "DISEASE", 124, 135], ["hydroxychloroquine", "CHEMICAL", 227, 245], ["azithromycin", "CHEMICAL", 250, 262], ["lung cancer", "DISEASE", 286, 297], ["lung cancer", "DISEASE", 571, 582], ["hydroxychloroquine", "CHEMICAL", 227, 245], ["azithromycin", "CHEMICAL", 250, 262], ["Lung cancer", "CANCER", 13, 24], ["lung cancer", "CANCER", 124, 135], ["patients", "ORGANISM", 136, 144], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 227, 245], ["azithromycin", "SIMPLE_CHEMICAL", 250, 262], ["lung cancer", "CANCER", 286, 297], ["patients", "ORGANISM", 298, 306], ["lung cancer", "CANCER", 571, 582], ["patients", "ORGANISM", 672, 680], ["patients", "SPECIES", 136, 144], ["patients", "SPECIES", 298, 306], ["patients", "SPECIES", 672, 680], ["Lung cancer", "PROBLEM", 13, 24], ["complications", "PROBLEM", 99, 112], ["Elderly lung cancer", "PROBLEM", 116, 135], ["Covid-19 related complications", "PROBLEM", 169, 199], ["hydroxychloroquine", "TREATMENT", 227, 245], ["azithromycin", "TREATMENT", 250, 262], ["lung cancer", "PROBLEM", 286, 297], ["the Covid", "TEST", 549, 558], ["infected lung cancer", "PROBLEM", 562, 582], ["Lung", "ANATOMY", 13, 17], ["cancer", "OBSERVATION", 18, 24], ["lung", "ANATOMY", 124, 128], ["cancer", "OBSERVATION", 129, 135], ["lung", "ANATOMY", 286, 290], ["cancer", "OBSERVATION", 291, 297], ["lung", "ANATOMY", 571, 575], ["cancer", "OBSERVATION", 576, 582]]], ["In our study we determine whether exists differences in cumulative incidence and severity of Covid-19 infection between lung cancer patients visiting our Medical Oncology department and the reference population of our center (320,000 people), in the current epicenter of the pandemic in Europe (Madrid, Spain).", [["lung cancer", "ANATOMY", 120, 131], ["infection", "DISEASE", 102, 111], ["lung cancer", "DISEASE", 120, 131], ["lung cancer", "CANCER", 120, 131], ["patients", "ORGANISM", 132, 140], ["people", "ORGANISM", 234, 240], ["patients", "SPECIES", 132, 140], ["people", "SPECIES", 234, 240], ["Covid-19", "SPECIES", 93, 101], ["our study", "TEST", 3, 12], ["Covid-19 infection between lung cancer", "PROBLEM", 93, 131], ["infection", "OBSERVATION", 102, 111], ["lung", "ANATOMY", 120, 124], ["cancer", "OBSERVATION", 125, 131]]], ["We also describe clinical and demographic factors associated with poor prognosis and Covid-19 treatment outcomes.Patients and methods:We retrospectively reviewed 1878 medical records of all Covid-19 patients who were admitted at Hospital Universitario Infanta Leonor of Madrid between March 5, 2020 and April 7, 2020, in order to detect cumulative incidence of Covid-19 in lung cancer patients.", [["lung cancer", "ANATOMY", 373, 384], ["lung cancer", "DISEASE", 373, 384], ["Patients", "ORGANISM", 113, 121], ["patients", "ORGANISM", 199, 207], ["lung cancer", "CANCER", 373, 384], ["patients", "ORGANISM", 385, 393], ["Patients", "SPECIES", 113, 121], ["patients", "SPECIES", 199, 207], ["patients", "SPECIES", 385, 393], ["poor prognosis", "PROBLEM", 66, 80], ["Covid-19 treatment outcomes", "TREATMENT", 85, 112], ["Covid", "TEST", 361, 366], ["lung cancer", "PROBLEM", 373, 384], ["lung", "ANATOMY", 373, 377], ["cancer", "OBSERVATION", 378, 384]]], ["We also described Covid-19 treatment outcome, mortality and associated risk factors using univariate and multivariate logistic regression analysis.Results:17/1878 total diagnosis in our center had lung cancer (0.9%) versus 1878/320,000 of the total reference population (p=0.09).", [["lung cancer", "ANATOMY", 197, 208], ["lung cancer", "DISEASE", 197, 208], ["lung cancer", "CANCER", 197, 208], ["Covid", "TEST", 18, 23], ["multivariate logistic regression analysis", "TEST", 105, 146], ["lung cancer", "PROBLEM", 197, 208], ["lung", "ANATOMY", 197, 201], ["cancer", "OBSERVATION", 202, 208]]], ["9/17 lung cancer patients with Covid-19 diagnosis died (52.3%) versus 192/1878 Covid-19 patients in our center (p<0.0001).", [["lung cancer", "ANATOMY", 5, 16], ["lung cancer", "DISEASE", 5, 16], ["lung cancer", "CANCER", 5, 16], ["patients", "ORGANISM", 17, 25], ["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 17, 25], ["patients", "SPECIES", 88, 96], ["lung cancer", "PROBLEM", 5, 16], ["Covid", "TEST", 31, 36], ["Covid", "TEST", 79, 84], ["lung", "ANATOMY", 5, 9], ["cancer", "OBSERVATION", 10, 16]]], ["Dead lung cancer patients were elderly compared to survivors: 72 versus 64.5 years old (p=0.12).", [["lung cancer", "ANATOMY", 5, 16], ["lung cancer", "DISEASE", 5, 16], ["lung cancer", "CANCER", 5, 16], ["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["Dead lung cancer", "PROBLEM", 0, 16], ["lung", "ANATOMY", 5, 9], ["cancer", "OBSERVATION", 10, 16]]], ["Combined treatment with hydroxychloroquine and azithromycin improves the outcome of Covid-19 in lung cancer patients, detecting only 1/6 deaths between patients under this Introduction In December 2019, multiple cases of atypical pneumonia of unknown origin were detected in China.", [["lung cancer", "ANATOMY", 96, 107], ["hydroxychloroquine", "CHEMICAL", 24, 42], ["azithromycin", "CHEMICAL", 47, 59], ["Covid-19", "CHEMICAL", 84, 92], ["lung cancer", "DISEASE", 96, 107], ["deaths", "DISEASE", 137, 143], ["pneumonia", "DISEASE", 230, 239], ["hydroxychloroquine", "CHEMICAL", 24, 42], ["azithromycin", "CHEMICAL", 47, 59], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 24, 42], ["azithromycin", "SIMPLE_CHEMICAL", 47, 59], ["lung cancer", "CANCER", 96, 107], ["patients", "ORGANISM", 108, 116], ["patients", "ORGANISM", 152, 160], ["patients", "SPECIES", 108, 116], ["patients", "SPECIES", 152, 160], ["hydroxychloroquine", "TREATMENT", 24, 42], ["azithromycin", "TREATMENT", 47, 59], ["Covid", "TEST", 84, 89], ["atypical pneumonia", "PROBLEM", 221, 239], ["lung", "ANATOMY", 96, 100], ["cancer", "OBSERVATION", 101, 107], ["atypical", "OBSERVATION_MODIFIER", 221, 229], ["pneumonia", "OBSERVATION", 230, 239], ["unknown origin", "OBSERVATION_MODIFIER", 243, 257]]], ["At the same time, a new coronavirus subtype was discovered as the etiology behind these described cases in Wuhan, Hubei (China).", [["coronavirus", "DISEASE", 24, 35], ["coronavirus", "ORGANISM", 24, 35], ["a new coronavirus subtype", "PROBLEM", 18, 43], ["new", "OBSERVATION_MODIFIER", 20, 23], ["coronavirus", "OBSERVATION", 24, 35]]], ["This novel microorganism detected, called as severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), has an enormous virulence and a high human-to-human transmission capacity [1] [2] .", [["acute respiratory syndrome coronavirus", "DISEASE", 52, 90], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 45, 92], ["SARS-COV-2", "ORGANISM", 94, 104], ["human", "ORGANISM", 144, 149], ["human", "ORGANISM", 153, 158], ["human", "SPECIES", 144, 149], ["human", "SPECIES", 153, 158], ["severe acute respiratory syndrome coronavirus", "SPECIES", 45, 90], ["SARS-COV-2", "SPECIES", 94, 104], ["human", "SPECIES", 144, 149], ["human", "SPECIES", 153, 158], ["This novel microorganism", "PROBLEM", 0, 24], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 45, 90], ["SARS", "TEST", 94, 98], ["COV", "TEST", 99, 102], ["an enormous virulence", "PROBLEM", 111, 132], ["severe", "OBSERVATION_MODIFIER", 45, 51], ["acute", "OBSERVATION_MODIFIER", 52, 57], ["respiratory syndrome", "OBSERVATION", 58, 78], ["enormous", "OBSERVATION_MODIFIER", 114, 122], ["virulence", "OBSERVATION", 123, 132]]], ["Thanks to its virulence, the SARS-COV-2 has been able to spread throughout the world, creating the unprecedented pandemic in which we are involved.", [["SARS", "DISEASE", 29, 33]]], ["Although the new coronavirus has a high human-to-human capacity transmission, it had a lower mortality than other previously isolated coronaviruses [3] .", [["coronavirus", "DISEASE", 17, 28], ["coronavirus", "ORGANISM", 17, 28], ["human", "ORGANISM", 40, 45], ["human", "ORGANISM", 49, 54], ["human", "SPECIES", 40, 45], ["human", "SPECIES", 49, 54], ["human", "SPECIES", 40, 45], ["human", "SPECIES", 49, 54], ["the new coronavirus", "PROBLEM", 9, 28], ["a lower mortality than other previously isolated coronaviruses", "PROBLEM", 85, 147], ["new", "OBSERVATION_MODIFIER", 13, 16], ["coronavirus", "OBSERVATION", 17, 28], ["high", "OBSERVATION_MODIFIER", 35, 39], ["coronaviruses", "OBSERVATION", 134, 147]]], ["However, the virus is capable of developing serious bilateral pneumonias and worrying inflammatory responses [4] .Results:On January 31, 2020, the first case of coronavirus was detected in Spain, in La Gomera Island.", [["pneumonias", "DISEASE", 62, 72], ["coronavirus", "DISEASE", 161, 172], ["coronavirus", "ORGANISM", 161, 172], ["the virus", "PROBLEM", 9, 18], ["developing serious bilateral pneumonias", "PROBLEM", 33, 72], ["worrying inflammatory responses", "PROBLEM", 77, 108], ["coronavirus", "PROBLEM", 161, 172], ["virus", "OBSERVATION", 13, 18], ["serious", "OBSERVATION_MODIFIER", 44, 51], ["bilateral", "ANATOMY_MODIFIER", 52, 61], ["pneumonias", "OBSERVATION", 62, 72], ["coronavirus", "OBSERVATION", 161, 172], ["La", "ANATOMY_MODIFIER", 199, 201], ["Gomera Island", "OBSERVATION", 202, 215]]], ["However, it was not until February 25, 2020, when the first case took place in Madrid, the most active focus currently in Europe.", [["active", "OBSERVATION_MODIFIER", 96, 102], ["focus", "OBSERVATION", 103, 108]]], ["A few days after the detection of the first case in Madrid, the health alert was declared, detecting an intracommunity transmission in Spain.", [["the detection", "TEST", 17, 30]]], ["In those moments, the infectious outbreak was classified as a pandemic by the world health organization (WHO) due to its extension.", [["the infectious outbreak", "PROBLEM", 18, 41], ["its extension", "PROBLEM", 117, 130], ["infectious", "OBSERVATION_MODIFIER", 22, 32]]], ["This unprecedented fact has changed the activity of the hospitals focusing on the diagnosis and treatment of the patients with Covid-19.Results:Cancer patients are at increased risk of Covid-19 infection.", [["Cancer", "ANATOMY", 144, 150], ["Cancer", "DISEASE", 144, 150], ["infection", "DISEASE", 194, 203], ["patients", "ORGANISM", 113, 121], ["Cancer", "CANCER", 144, 150], ["patients", "ORGANISM", 151, 159], ["Covid-19", "ORGANISM", 185, 193], ["patients", "SPECIES", 113, 121], ["patients", "SPECIES", 151, 159], ["Covid-19", "SPECIES", 185, 193], ["treatment", "TREATMENT", 96, 105], ["Covid", "TEST", 127, 132], ["Cancer", "PROBLEM", 144, 150], ["Covid-19 infection", "PROBLEM", 185, 203], ["Cancer", "OBSERVATION", 144, 150], ["infection", "OBSERVATION", 194, 203]]], ["These patients must maintain their visits to Oncology departments.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14]]], ["They should continue receiving their diagnoses and treatments to avoid complications from their own oncological pathology [5] .Results:In some reports, it has been described that the risk-benefit should be assessed in the planning of visits and treatments in cancer patients [6] as well as in patients with only lung cancer diagnosis, trying to make as few visits as possible [7] .", [["cancer", "ANATOMY", 259, 265], ["lung cancer", "ANATOMY", 312, 323], ["cancer", "DISEASE", 259, 265], ["lung cancer", "DISEASE", 312, 323], ["cancer", "CANCER", 259, 265], ["patients", "ORGANISM", 266, 274], ["patients", "ORGANISM", 293, 301], ["lung cancer", "CANCER", 312, 323], ["patients", "SPECIES", 266, 274], ["patients", "SPECIES", 293, 301], ["treatments", "TREATMENT", 51, 61], ["complications", "PROBLEM", 71, 84], ["treatments", "TREATMENT", 245, 255], ["lung cancer", "PROBLEM", 312, 323], ["lung", "ANATOMY", 312, 316], ["cancer", "OBSERVATION", 317, 323]]], ["In a study carried out by Yu J. in China, they described how patients with non-small cell lung cancer (NSCLC) have a higher incidence and severity of Covid-19 [8] .", [["non-small cell lung cancer", "ANATOMY", 75, 101], ["NSCLC", "ANATOMY", 103, 108], ["non-small cell lung cancer", "DISEASE", 75, 101], ["NSCLC", "DISEASE", 103, 108], ["patients", "ORGANISM", 61, 69], ["non-small cell lung cancer", "CANCER", 75, 101], ["NSCLC", "CANCER", 103, 108], ["patients", "SPECIES", 61, 69], ["a study", "TEST", 3, 10], ["non-small cell lung cancer", "PROBLEM", 75, 101], ["NSCLC", "PROBLEM", 103, 108], ["Covid", "TEST", 150, 155], ["non-small cell", "OBSERVATION", 75, 89], ["lung", "ANATOMY", 90, 94], ["cancer", "OBSERVATION", 95, 101]]], ["However, in other studies, they described an increase in the cumulative incidence of Covid-19 in all cancer population.", [["cancer", "ANATOMY", 101, 107], ["cancer", "DISEASE", 101, 107], ["cancer", "CANCER", 101, 107], ["other studies", "TEST", 12, 25], ["Covid", "TEST", 85, 90], ["all cancer population", "PROBLEM", 97, 118], ["increase", "OBSERVATION_MODIFIER", 45, 53], ["cumulative", "OBSERVATION_MODIFIER", 61, 71], ["cancer", "OBSERVATION", 101, 107]]], ["They did not describe a greater severity in patients with lung cancer [9] [10] .Results:In our study, we determine whether exists differences in cumulative incidence and severity of Covid-19 infection between lung cancer patients visiting our Medical Oncology department and the reference population of our center (320,000 people), in the current epicenter of the pandemic in Europe (Madrid, Spain).", [["lung cancer", "ANATOMY", 58, 69], ["lung cancer", "ANATOMY", 209, 220], ["lung cancer", "DISEASE", 58, 69], ["infection", "DISEASE", 191, 200], ["lung cancer", "DISEASE", 209, 220], ["patients", "ORGANISM", 44, 52], ["lung cancer", "CANCER", 58, 69], ["lung cancer", "CANCER", 209, 220], ["patients", "ORGANISM", 221, 229], ["people", "ORGANISM", 323, 329], ["patients", "SPECIES", 44, 52], ["patients", "SPECIES", 221, 229], ["people", "SPECIES", 323, 329], ["Covid-19", "SPECIES", 182, 190], ["lung cancer", "PROBLEM", 58, 69], ["our study", "TEST", 91, 100], ["Covid-19 infection between lung cancer", "PROBLEM", 182, 220], ["lung", "ANATOMY", 58, 62], ["cancer", "OBSERVATION", 63, 69], ["lung", "ANATOMY", 209, 213], ["cancer", "OBSERVATION", 214, 220]]], ["We also describe clinical and demographic factors associated with poor prognosis and Covid-19 treatment outcomes.Material and methodsWe retrospectively reviewed 1878 medical records of all patients with Covid-19 diagnosis admitted at Hospital Universitario Infanta Leonor of Madrid, since the first Covid-19 diagnosis date, March 5, 2020, to April 7, 2020.", [["patients", "ORGANISM", 189, 197], ["patients", "SPECIES", 189, 197], ["poor prognosis", "PROBLEM", 66, 80], ["Covid-19 treatment outcomes", "TREATMENT", 85, 112]]], ["We studied cumulative incidence of Covid-19 infection and its mortality in lung cancer patients.", [["lung cancer", "ANATOMY", 75, 86], ["infection", "DISEASE", 44, 53], ["lung cancer", "DISEASE", 75, 86], ["lung cancer", "CANCER", 75, 86], ["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95], ["Covid-19", "SPECIES", 35, 43], ["Covid-19 infection", "PROBLEM", 35, 53], ["lung cancer", "PROBLEM", 75, 86], ["infection", "OBSERVATION", 44, 53], ["lung", "ANATOMY", 75, 79], ["cancer", "OBSERVATION", 80, 86]]], ["Covid-19 diagnosis was made based on WHO criteria and/or confirmed by RT-PCR of naso-pharingeal specimens.Material and methodsDescriptive analyses are reported as relative frequencies for discrete variables.", [["naso-pharingeal specimens", "ANATOMY", 80, 105], ["naso-pharingeal specimens", "CANCER", 80, 105], ["RT-PCR", "TEST", 70, 76], ["Descriptive analyses", "TEST", 126, 146]]], ["Continuous variables are reported as mean \u00b1 standard deviation (SD) or median and interquartile range (IQR) for normal and not normally distributed variables, respectively.", [["mean \u00b1 standard deviation (SD)", "PROBLEM", 37, 67], ["normal", "OBSERVATION", 112, 118], ["distributed", "OBSERVATION_MODIFIER", 136, 147]]], ["To determine differences on mortality between lung cancer patients and general population, Fisher\u00b4s Exact Test were performed.", [["lung cancer", "ANATOMY", 46, 57], ["lung cancer", "DISEASE", 46, 57], ["lung cancer", "CANCER", 46, 57], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["lung cancer", "PROBLEM", 46, 57], ["Fisher\u00b4s Exact Test", "TEST", 91, 110], ["lung", "ANATOMY", 46, 50], ["cancer", "OBSERVATION", 51, 57]]], ["To determine the relationship between clinical and demographic risk factors with mortality, Chi square Test, univariate logistic regression and multivariate logistic regression were performed.", [["Chi square Test", "TEST", 92, 107], ["multivariate logistic regression", "TEST", 144, 176]]], ["Statistical analyses were carried out with STATA SE version 14.1 (StataCorp, College Station, TX, USA).", [["Statistical analyses", "TEST", 0, 20], ["STATA SE version", "TEST", 43, 59]]], ["A p-value <0.05 was considered statistically significant.ResultsSeventeen cases of lung cancer with Covid-19 infection were detected in our center.", [["lung cancer", "ANATOMY", 83, 94], ["lung cancer", "DISEASE", 83, 94], ["Covid-19 infection", "DISEASE", 100, 118], ["lung cancer", "CANCER", 83, 94], ["Covid-19", "SPECIES", 100, 108], ["A p-value", "TEST", 0, 9], ["lung cancer", "PROBLEM", 83, 94], ["Covid-19 infection", "PROBLEM", 100, 118], ["lung", "ANATOMY", 83, 87], ["cancer", "OBSERVATION", 88, 94], ["infection", "OBSERVATION", 109, 118]]], ["Most frequent histology was non-small cell lung cancer (n=16, 94.1%).", [["non-small cell lung cancer", "ANATOMY", 28, 54], ["non-small cell lung cancer", "DISEASE", 28, 54], ["non-small cell lung cancer", "CANCER", 28, 54], ["non-small cell lung cancer", "PROBLEM", 28, 54], ["non-small cell", "OBSERVATION", 28, 42], ["lung", "ANATOMY", 43, 47], ["cancer", "OBSERVATION", 48, 54]]], ["Most affected patients had metastatic disease (n=11, 64.7%) and received chemotherapy (n=5, 29.4%).", [["metastatic disease", "ANATOMY", 27, 45], ["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["metastatic disease", "PROBLEM", 27, 45], ["chemotherapy", "TREATMENT", 73, 85], ["metastatic", "OBSERVATION", 27, 37]]], ["All patients who were able to receive treatment for Covid-19 infection received hydroxychloroquine (n=12, 70.6%), most combined with azithromycin (n=8, 47.1%).", [["infection", "DISEASE", 61, 70], ["hydroxychloroquine", "CHEMICAL", 80, 98], ["azithromycin", "CHEMICAL", 133, 145], ["hydroxychloroquine", "CHEMICAL", 80, 98], ["azithromycin", "CHEMICAL", 133, 145], ["patients", "ORGANISM", 4, 12], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 80, 98], ["azithromycin", "SIMPLE_CHEMICAL", 133, 145], ["patients", "SPECIES", 4, 12], ["Covid-19", "SPECIES", 52, 60], ["treatment", "TREATMENT", 38, 47], ["Covid-19 infection", "PROBLEM", 52, 70], ["hydroxychloroquine", "TREATMENT", 80, 98], ["azithromycin", "TREATMENT", 133, 145]]], ["All patients required admission except for 4 patients (76.5%), 11 of them being diagnosed with severe Covid-19 infection (64.7%).", [["Covid-19 infection", "DISEASE", 102, 120], ["patients", "ORGANISM", 4, 12], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 45, 53], ["Covid-19", "SPECIES", 102, 110], ["severe Covid-19 infection", "PROBLEM", 95, 120], ["severe", "OBSERVATION_MODIFIER", 95, 101], ["infection", "OBSERVATION", 111, 120]]], ["None of the patients were admitted to the ICU, either because they did not need it, or because it was not admitted due to their comorbidities.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["their comorbidities", "PROBLEM", 122, 141]]], ["About comorbidities, 10 patients had hypertension (51.1%), 9 patients Chronic Obstructive Pulmonary Disease (COPD) (52.4%), 3 patients obesity (17.6%), 2 patients diabetes (11.7%) and 1 patient chronic kidney disease (5.8%).", [["Pulmonary", "ANATOMY", 90, 99], ["kidney", "ANATOMY", 202, 208], ["hypertension", "DISEASE", 37, 49], ["Chronic Obstructive Pulmonary Disease", "DISEASE", 70, 107], ["COPD", "DISEASE", 109, 113], ["obesity", "DISEASE", 135, 142], ["diabetes", "DISEASE", 163, 171], ["chronic kidney disease", "DISEASE", 194, 216], ["patients", "ORGANISM", 24, 32], ["patients", "ORGANISM", 61, 69], ["Pulmonary", "ORGAN", 90, 99], ["patients", "ORGANISM", 126, 134], ["patients", "ORGANISM", 154, 162], ["patient", "ORGANISM", 186, 193], ["kidney", "ORGAN", 202, 208], ["patients", "SPECIES", 24, 32], ["patients", "SPECIES", 61, 69], ["patients", "SPECIES", 126, 134], ["patients", "SPECIES", 154, 162], ["patient", "SPECIES", 186, 193], ["hypertension", "PROBLEM", 37, 49], ["Chronic Obstructive Pulmonary Disease (COPD)", "PROBLEM", 70, 114], ["3 patients obesity", "PROBLEM", 124, 142], ["2 patients diabetes", "PROBLEM", 152, 171], ["1 patient chronic kidney disease", "PROBLEM", 184, 216], ["hypertension", "OBSERVATION", 37, 49], ["Chronic", "OBSERVATION_MODIFIER", 70, 77], ["Obstructive", "OBSERVATION_MODIFIER", 78, 89], ["Pulmonary", "ANATOMY", 90, 99], ["Disease", "OBSERVATION", 100, 107], ["COPD", "OBSERVATION", 109, 113], ["chronic", "OBSERVATION_MODIFIER", 194, 201], ["kidney", "ANATOMY", 202, 208], ["disease", "OBSERVATION", 209, 216]]], ["Table 1 .ResultsSeventeen cases of lung cancer with Covid-19 infection were detected among the 45 cancer patients (37.7%), which supposes a cumulative incidence of 0.9% on the total of 1878 infected patients at data cut off versus 0.58% in our reference population (1878 patients of 320,000 inhabitants, Fisher's exact test, p=0.09).", [["lung cancer", "ANATOMY", 35, 46], ["cancer", "ANATOMY", 98, 104], ["lung cancer", "DISEASE", 35, 46], ["Covid-19 infection", "DISEASE", 52, 70], ["cancer", "DISEASE", 98, 104], ["lung cancer", "CANCER", 35, 46], ["cancer", "CANCER", 98, 104], ["patients", "ORGANISM", 105, 113], ["patients", "ORGANISM", 199, 207], ["patients", "ORGANISM", 271, 279], ["patients", "SPECIES", 105, 113], ["patients", "SPECIES", 199, 207], ["patients", "SPECIES", 271, 279], ["Covid-19", "SPECIES", 52, 60], ["lung cancer", "PROBLEM", 35, 46], ["Covid-19 infection", "PROBLEM", 52, 70], ["Fisher's exact test", "TEST", 304, 323], ["lung", "ANATOMY", 35, 39], ["cancer", "OBSERVATION", 40, 46], ["infection", "OBSERVATION", 61, 70]]], ["Regarding mortality, we detected that 9/17 patients (52.3%) with lung cancer died versus 192 over the total of 1878 Covid-19 patients in our center (Fisher's exact test, p<0.0001).", [["lung cancer", "ANATOMY", 65, 76], ["lung cancer", "DISEASE", 65, 76], ["patients", "ORGANISM", 43, 51], ["lung cancer", "CANCER", 65, 76], ["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 43, 51], ["patients", "SPECIES", 125, 133], ["lung cancer", "PROBLEM", 65, 76], ["Fisher's exact test", "TEST", 149, 168], ["lung", "ANATOMY", 65, 69], ["cancer", "OBSERVATION", 70, 76]]], ["Regarding dead lung cancer patients, two patients were under chemotherapy, two patients under best supportive care, one patient under checkpoint inhibitor treatment (nivolumab), one patient under tyrosine kinase inhibitor (gefitinib), one patient underwent surgery and two patients were new diagnosis.", [["lung cancer", "ANATOMY", 15, 26], ["lung cancer", "DISEASE", 15, 26], ["tyrosine", "CHEMICAL", 196, 204], ["gefitinib", "CHEMICAL", 223, 232], ["tyrosine", "CHEMICAL", 196, 204], ["gefitinib", "CHEMICAL", 223, 232], ["dead lung cancer", "CANCER", 10, 26], ["patients", "ORGANISM", 27, 35], ["patients", "ORGANISM", 41, 49], ["patients", "ORGANISM", 79, 87], ["patient", "ORGANISM", 120, 127], ["nivolumab", "SIMPLE_CHEMICAL", 166, 175], ["patient", "ORGANISM", 182, 189], ["gefitinib", "SIMPLE_CHEMICAL", 223, 232], ["patient", "ORGANISM", 239, 246], ["patients", "ORGANISM", 273, 281], ["patients", "SPECIES", 27, 35], ["patients", "SPECIES", 41, 49], ["patients", "SPECIES", 79, 87], ["patient", "SPECIES", 120, 127], ["patient", "SPECIES", 182, 189], ["patient", "SPECIES", 239, 246], ["patients", "SPECIES", 273, 281], ["dead lung cancer", "PROBLEM", 10, 26], ["chemotherapy", "TREATMENT", 61, 73], ["best supportive care", "TREATMENT", 94, 114], ["checkpoint inhibitor treatment", "TREATMENT", 134, 164], ["nivolumab", "TREATMENT", 166, 175], ["tyrosine kinase inhibitor", "TREATMENT", 196, 221], ["gefitinib", "TREATMENT", 223, 232], ["surgery", "TREATMENT", 257, 264], ["lung", "ANATOMY", 15, 19], ["cancer", "OBSERVATION", 20, 26]]], ["A trend towards statistical significance was detected in the mean age between the patients with lung cancer who died and those who are still alive: 72 versus 64.5 years old in the survivors' subgroup (p=0.12).", [["lung cancer", "ANATOMY", 96, 107], ["lung cancer", "DISEASE", 96, 107], ["patients", "ORGANISM", 82, 90], ["lung cancer", "CANCER", 96, 107], ["patients", "SPECIES", 82, 90], ["lung cancer", "PROBLEM", 96, 107], ["lung", "ANATOMY", 96, 100], ["cancer", "OBSERVATION", 101, 107]]], ["No other associations between mortality and other clinical demographic variables, patient's symptoms or comorbidities were detected.ResultsCombined treatment with hydroxychloroquine and azithromycin improves the outcome of Covid-19 lung cancer patients, detecting only 1/8 deaths between patients under this treatment (OR 0.04, CI 0.01-0.57, p=0.018).", [["lung cancer", "ANATOMY", 232, 243], ["hydroxychloroquine", "CHEMICAL", 163, 181], ["azithromycin", "CHEMICAL", 186, 198], ["lung cancer", "DISEASE", 232, 243], ["deaths", "DISEASE", 273, 279], ["hydroxychloroquine", "CHEMICAL", 163, 181], ["azithromycin", "CHEMICAL", 186, 198], ["patient", "ORGANISM", 82, 89], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 163, 181], ["azithromycin", "SIMPLE_CHEMICAL", 186, 198], ["Covid-19 lung cancer", "CANCER", 223, 243], ["patients", "ORGANISM", 244, 252], ["patients", "ORGANISM", 288, 296], ["patient", "SPECIES", 82, 89], ["patients", "SPECIES", 244, 252], ["patients", "SPECIES", 288, 296], ["patient's symptoms", "PROBLEM", 82, 100], ["comorbidities", "PROBLEM", 104, 117], ["hydroxychloroquine", "TREATMENT", 163, 181], ["azithromycin", "TREATMENT", 186, 198], ["Covid", "TEST", 223, 228], ["lung cancer", "PROBLEM", 232, 243], ["this treatment", "TREATMENT", 303, 317], ["CI", "TEST", 328, 330], ["lung", "ANATOMY", 232, 236], ["cancer", "OBSERVATION", 237, 243]]], ["Similar results were observed in the multivariate logistic regression adjusted by age (OR 0.02, CI 0.001-0.588, p=0.02).DiscussionIn our study, a significant increase in mortality rate in lung cancer patients with Covid-19 was detected compared to all Covid-19 patients in our center.", [["lung cancer", "ANATOMY", 188, 199], ["lung cancer", "DISEASE", 188, 199], ["lung cancer", "CANCER", 188, 199], ["patients", "ORGANISM", 200, 208], ["patients", "ORGANISM", 261, 269], ["patients", "SPECIES", 200, 208], ["patients", "SPECIES", 261, 269], ["CI", "TEST", 96, 98], ["our study", "TEST", 133, 142], ["a significant increase in mortality rate", "PROBLEM", 144, 184], ["lung cancer", "PROBLEM", 188, 199], ["Covid", "TEST", 214, 219], ["significant", "OBSERVATION_MODIFIER", 146, 157], ["increase", "OBSERVATION_MODIFIER", 158, 166], ["lung", "ANATOMY", 188, 192], ["cancer", "OBSERVATION", 193, 199]]], ["Considering the characteristics of the lung cancer patients, with a greater predisposition to respiratory infections, immunosuppressed patients, and most of them with a previous diagnosis of COPD and metastatic disease, we expected to observe greater mortality or, at least, greater severity of the infectious symptoms.DiscussionIn three Chinese series performed with heterogeneous samples of cancer patients, they described that the most frequent type of tumor in their series was lung cancer [8] [9] [10] .", [["lung cancer", "ANATOMY", 39, 50], ["respiratory", "ANATOMY", 94, 105], ["samples", "ANATOMY", 382, 389], ["cancer", "ANATOMY", 393, 399], ["tumor", "ANATOMY", 456, 461], ["lung cancer", "ANATOMY", 482, 493], ["lung cancer", "DISEASE", 39, 50], ["respiratory infections", "DISEASE", 94, 116], ["COPD", "DISEASE", 191, 195], ["cancer", "DISEASE", 393, 399], ["tumor", "DISEASE", 456, 461], ["lung cancer", "DISEASE", 482, 493], ["lung cancer", "CANCER", 39, 50], ["patients", "ORGANISM", 51, 59], ["patients", "ORGANISM", 135, 143], ["cancer", "CANCER", 393, 399], ["patients", "ORGANISM", 400, 408], ["tumor", "CANCER", 456, 461], ["lung cancer", "CANCER", 482, 493], ["patients", "SPECIES", 51, 59], ["patients", "SPECIES", 135, 143], ["patients", "SPECIES", 400, 408], ["the lung cancer", "PROBLEM", 35, 50], ["respiratory infections", "PROBLEM", 94, 116], ["COPD", "PROBLEM", 191, 195], ["metastatic disease", "PROBLEM", 200, 218], ["the infectious symptoms", "PROBLEM", 295, 318], ["cancer", "PROBLEM", 393, 399], ["tumor", "PROBLEM", 456, 461], ["lung cancer", "PROBLEM", 482, 493], ["lung", "ANATOMY", 39, 43], ["cancer", "OBSERVATION", 44, 50], ["respiratory", "ANATOMY", 94, 105], ["infections", "OBSERVATION", 106, 116], ["COPD", "OBSERVATION", 191, 195], ["metastatic", "OBSERVATION", 200, 210], ["infectious", "OBSERVATION", 299, 309], ["cancer", "OBSERVATION", 393, 399], ["tumor", "OBSERVATION", 456, 461], ["lung", "ANATOMY", 482, 486], ["cancer", "OBSERVATION", 487, 493]]], ["However, only one of them described a higher susceptibility and severity for Covid-19 in NSCLC [9] .", [["NSCLC", "ANATOMY", 89, 94], ["NSCLC", "DISEASE", 89, 94], ["NSCLC", "CANCER", 89, 94], ["a higher susceptibility and severity", "PROBLEM", 36, 72], ["Covid", "TEST", 77, 82], ["NSCLC", "PROBLEM", 89, 94], ["NSCLC", "OBSERVATION", 89, 94]]], ["In the other two remaining studies, they indicated that this population is the most frequently infected as we previously have indicated [9] [10] .", [["remaining studies", "TEST", 17, 34]]], ["Nevertheless in the study by Liang W did not find that lung cancer patients had a higher risk of complications compared to the rest of the oncology population from their work [9] .", [["lung cancer", "ANATOMY", 55, 66], ["lung cancer", "DISEASE", 55, 66], ["lung cancer", "CANCER", 55, 66], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["the study", "TEST", 16, 25], ["lung cancer", "PROBLEM", 55, 66], ["complications", "PROBLEM", 97, 110], ["lung", "ANATOMY", 55, 59], ["cancer", "OBSERVATION", 60, 66], ["complications", "OBSERVATION", 97, 110]]], ["These results are likely to be found in this study because most of its patients were cancer survivors.", [["cancer", "ANATOMY", 85, 91], ["cancer", "DISEASE", 85, 91], ["patients", "ORGANISM", 71, 79], ["cancer", "CANCER", 85, 91], ["patients", "SPECIES", 71, 79], ["this study", "TEST", 40, 50], ["cancer survivors", "PROBLEM", 85, 101], ["cancer", "OBSERVATION", 85, 91]]], ["In our study, most of the lung cancer patients had active disease or were on active treatment.", [["lung cancer", "ANATOMY", 26, 37], ["lung cancer", "DISEASE", 26, 37], ["lung cancer", "CANCER", 26, 37], ["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["our study", "TEST", 3, 12], ["the lung cancer", "PROBLEM", 22, 37], ["active disease", "PROBLEM", 51, 65], ["active treatment", "TREATMENT", 77, 93], ["lung", "ANATOMY", 26, 30], ["cancer", "OBSERVATION", 31, 37], ["active", "OBSERVATION_MODIFIER", 51, 57], ["disease", "OBSERVATION", 58, 65], ["active", "OBSERVATION_MODIFIER", 77, 83]]], ["They observed a lower mortality rate (33.3%), but they also agree that a determining fact in these deaths, was the refusal to ICU admission.", [["deaths", "DISEASE", 99, 105], ["a lower mortality rate", "TEST", 14, 36]]], ["Furthermore, none of these three published studies [9] [10] [11] provide specific data on Covid-19 treatment outcome.", [["[9] [10] [11]", "SIMPLE_CHEMICAL", 51, 64], ["specific data", "TEST", 73, 86], ["Covid", "TEST", 90, 95]]], ["In our study, we have checked in the multivariate analysis that hydroxychloroquine and azithromycin combination may be a good treatment option in patients with lung cancer with just one dead patient, but we cannot draw conclusions due to the limited number of cases of our study.DiscussionTo our knowledge, this is the one of the only homogeneous case series of lung cancer and Covid-19, and with many more lung cancer patients included than the individual analyses performed within the heterogeneous Chinese series, only being overtaken by preliminary data reported from Teravolt study [11] .", [["lung cancer", "ANATOMY", 160, 171], ["lung cancer", "ANATOMY", 362, 373], ["lung cancer", "ANATOMY", 407, 418], ["hydroxychloroquine", "CHEMICAL", 64, 82], ["azithromycin", "CHEMICAL", 87, 99], ["lung cancer", "DISEASE", 160, 171], ["lung cancer", "DISEASE", 362, 373], ["lung cancer", "DISEASE", 407, 418], ["hydroxychloroquine", "CHEMICAL", 64, 82], ["azithromycin", "CHEMICAL", 87, 99], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 64, 82], ["azithromycin", "SIMPLE_CHEMICAL", 87, 99], ["patients", "ORGANISM", 146, 154], ["lung cancer", "CANCER", 160, 171], ["patient", "ORGANISM", 191, 198], ["lung cancer", "CANCER", 362, 373], ["lung cancer", "CANCER", 407, 418], ["patients", "ORGANISM", 419, 427], ["patients", "SPECIES", 146, 154], ["patient", "SPECIES", 191, 198], ["patients", "SPECIES", 419, 427], ["our study", "TEST", 3, 12], ["hydroxychloroquine", "TREATMENT", 64, 82], ["azithromycin", "TREATMENT", 87, 99], ["a good treatment option", "TREATMENT", 119, 142], ["lung cancer", "PROBLEM", 160, 171], ["our study", "TEST", 269, 278], ["lung cancer", "PROBLEM", 362, 373], ["Covid", "TEST", 378, 383], ["many more lung cancer", "PROBLEM", 397, 418], ["the individual analyses", "TEST", 442, 465], ["Teravolt study", "TEST", 572, 586], ["lung", "ANATOMY", 160, 164], ["cancer", "OBSERVATION", 165, 171], ["lung", "ANATOMY", 362, 366], ["cancer", "OBSERVATION", 367, 373], ["lung", "ANATOMY", 407, 411], ["cancer", "OBSERVATION", 412, 418]]], ["Our work is the only one that provides data in lung cancer outcome to Covid-19 treatment.", [["lung cancer", "ANATOMY", 47, 58], ["lung cancer", "DISEASE", 47, 58], ["Covid-19", "CHEMICAL", 70, 78], ["lung cancer", "CANCER", 47, 58], ["lung cancer", "PROBLEM", 47, 58], ["Covid-19 treatment", "TREATMENT", 70, 88], ["lung", "ANATOMY", 47, 51], ["cancer", "OBSERVATION", 52, 58]]], ["However, there J o u r n a l P r e -p r o o f are some limitations: our study is a retrospective review, and despite being one of the largest ones focused on a single subtype of cancer, it still has a limited and heterogeneous number of patients.ConclusionLung cancer patients have a higher mortality rate than general population, with 52.3% of dead patients in our series.", [["cancer", "ANATOMY", 178, 184], ["ConclusionLung cancer", "ANATOMY", 246, 267], ["cancer", "DISEASE", 178, 184], ["ConclusionLung cancer", "DISEASE", 246, 267], ["cancer", "CANCER", 178, 184], ["patients", "ORGANISM", 237, 245], ["ConclusionLung cancer", "CANCER", 246, 267], ["patients", "ORGANISM", 268, 276], ["patients", "ORGANISM", 350, 358], ["patients", "SPECIES", 237, 245], ["patients", "SPECIES", 268, 276], ["patients", "SPECIES", 350, 358], ["our study", "TEST", 68, 77], ["a retrospective review", "TEST", 81, 103], ["cancer", "PROBLEM", 178, 184], ["ConclusionLung cancer", "PROBLEM", 246, 267], ["a higher mortality rate", "PROBLEM", 282, 305], ["largest", "OBSERVATION_MODIFIER", 134, 141], ["cancer", "OBSERVATION", 178, 184], ["heterogeneous", "OBSERVATION_MODIFIER", 213, 226], ["number", "OBSERVATION_MODIFIER", 227, 233], ["cancer", "OBSERVATION", 261, 267]]], ["Due to the high lethality in this subgroup of cancer patients, it is important to try to minimize visits to hospitals (without removing their active treatments) in order to decrease nosocomial transmission.", [["cancer", "ANATOMY", 46, 52], ["cancer", "DISEASE", 46, 52], ["cancer", "CANCER", 46, 52], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["the high lethality", "PROBLEM", 7, 25], ["their active treatments", "TREATMENT", 136, 159], ["high", "OBSERVATION_MODIFIER", 11, 15], ["lethality", "OBSERVATION", 16, 25], ["cancer", "OBSERVATION", 46, 52], ["nosocomial", "OBSERVATION", 182, 192]]]], "PMC7337653": [["This year health systems will not only face unprecedented financial challenges due to the coronavirus disease 2019 (COVID-19) pandemic; they may also be facing operational challenges.", [["coronavirus disease", "DISEASE", 90, 109], ["the coronavirus disease", "PROBLEM", 86, 109], ["pandemic", "PROBLEM", 126, 134]]], ["The section of the ASHP Foundation\u2019s 2020 Pharmacy Forecast report regarding \u201cblack swans\u201d (rare events with serious consequences, as popularized by Taleb2) noted that few health-system pharmacy departments had a strategic planning process in place to successfully deal with such an event.3 Meeting the patient surge and drug shortage challenges posed by the COVID-19 pandemic in addition to planning for costly new pharmaceuticals will test even the most robust organizations.", [["patient", "ORGANISM", 303, 310], ["patient", "SPECIES", 303, 310], ["black swans", "SPECIES", 78, 89], ["black swans", "PROBLEM", 78, 89], ["a strategic planning process", "TREATMENT", 211, 239], ["costly new pharmaceuticals", "TREATMENT", 405, 431]]]], "9424affcafd51079d7c0c1e5037674668fccabc8": [["more and longer medical therapies.", [["longer medical therapies", "TREATMENT", 9, 33]]], ["Immunoglobulin substitution therapy along with prophylactic antibiotics remained the cornerstone of treatment for PADs and related complications [2] .", [["PADs", "DISEASE", 114, 118], ["Immunoglobulin", "GENE_OR_GENE_PRODUCT", 0, 14], ["Immunoglobulin substitution therapy", "TREATMENT", 0, 35], ["prophylactic antibiotics", "TREATMENT", 47, 71], ["treatment for PADs", "TREATMENT", 100, 118], ["related complications", "PROBLEM", 123, 144]]], ["Generally, immunoglobulin replacement therapy can effectively reduce both incidence and severity of infections [2] .", [["infections", "DISEASE", 100, 110], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 11, 25], ["immunoglobulin", "PROTEIN", 11, 25], ["immunoglobulin replacement therapy", "TREATMENT", 11, 45], ["severity of infections", "PROBLEM", 88, 110], ["immunoglobulin replacement", "OBSERVATION", 11, 37], ["infections", "OBSERVATION", 100, 110]]], ["However, immunoglobulin products contain only purified IgG antibodies and lack other antibody isotypes.", [["immunoglobulin", "GENE_OR_GENE_PRODUCT", 9, 23], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 55, 69], ["immunoglobulin products", "PROTEIN", 9, 32], ["IgG antibodies", "PROTEIN", 55, 69], ["antibody isotypes", "PROTEIN", 85, 102], ["immunoglobulin products", "TREATMENT", 9, 32], ["purified IgG antibodies", "TEST", 46, 69], ["lack other antibody isotypes", "PROBLEM", 74, 102], ["IgG antibodies", "OBSERVATION", 55, 69], ["antibody isotypes", "OBSERVATION", 85, 102]]], ["It is thus expected that pulmonary infections may persist and even flourish under regular immunoglobulin replacement therapy.", [["pulmonary", "ANATOMY", 25, 34], ["pulmonary infections", "DISEASE", 25, 45], ["pulmonary", "ORGAN", 25, 34], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 90, 104], ["immunoglobulin", "PROTEIN", 90, 104], ["pulmonary infections", "PROBLEM", 25, 45], ["regular immunoglobulin replacement therapy", "TREATMENT", 82, 124], ["pulmonary", "ANATOMY", 25, 34], ["infections", "OBSERVATION", 35, 45], ["immunoglobulin replacement", "OBSERVATION", 90, 116]]], ["Thereby, the patient will be more predisposed to chronic lung diseases and related severe sequels such as respiratory failure [3] .", [["lung", "ANATOMY", 57, 61], ["respiratory", "ANATOMY", 106, 117], ["chronic lung diseases", "DISEASE", 49, 70], ["respiratory failure", "DISEASE", 106, 125], ["patient", "ORGANISM", 13, 20], ["lung", "ORGAN", 57, 61], ["patient", "SPECIES", 13, 20], ["chronic lung diseases", "PROBLEM", 49, 70], ["severe sequels", "PROBLEM", 83, 97], ["respiratory failure", "PROBLEM", 106, 125], ["chronic", "OBSERVATION_MODIFIER", 49, 56], ["lung", "ANATOMY", 57, 61], ["diseases", "OBSERVATION", 62, 70], ["severe", "OBSERVATION_MODIFIER", 83, 89], ["sequels", "OBSERVATION", 90, 97], ["respiratory failure", "OBSERVATION", 106, 125]]], ["Recent studies have identified a gap for screening protocols to monitor respiratory manifestations in patients with PADs [4] .", [["respiratory", "ANATOMY", 72, 83], ["respiratory manifestations", "DISEASE", 72, 98], ["PADs", "DISEASE", 116, 120], ["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110], ["Recent studies", "TEST", 0, 14], ["screening protocols", "TEST", 41, 60], ["respiratory manifestations", "PROBLEM", 72, 98]]]], "f7382e1a8b96d75cb66b8895f41562109a7b4192": [["According to a UK Office for National Statistics report in 2019 [2] there were 139,845 people in contact with drug services during the 2018/19 period; some of these will be opioid dependent but for many this will not be a single substance misuse.", [["people", "ORGANISM", 87, 93], ["people", "SPECIES", 87, 93], ["opioid dependent", "PROBLEM", 173, 189]]]], "PMC5414214": [["Methods ::: BackgroundFrom January 2004 to December 2014, all patients diagnosed with severe strongyloidiasis at the University of the Ryukyus Hospital or affiliated hospitals in Okinawa, Japan, were included in this retrospective study.", [["strongyloidiasis", "DISEASE", 93, 109], ["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["severe strongyloidiasis", "PROBLEM", 86, 109], ["this retrospective study", "TEST", 212, 236], ["severe", "OBSERVATION_MODIFIER", 86, 92], ["strongyloidiasis", "OBSERVATION", 93, 109]]], ["All diagnoses were confirmed by the microscopic identification of larvae using the agar plate culture method [11] or histopathological findings.", [["the microscopic identification", "TEST", 32, 62], ["the agar plate culture method", "TEST", 79, 108], ["histopathological findings", "TEST", 117, 143]]], ["For purposes of this study, severe strongyloidiasis was defined by the presence of any of the following: 1) the identification of S. stercoralis from extra gastrointestinal specimens, 2) sepsis, 3) meningitis, 4) acute respiratory failure, or 5) respiratory tract hemorrhage.", [["gastrointestinal specimens", "ANATOMY", 156, 182], ["respiratory", "ANATOMY", 219, 230], ["respiratory tract", "ANATOMY", 246, 263], ["strongyloidiasis", "DISEASE", 35, 51], ["S. stercoralis", "DISEASE", 130, 144], ["sepsis", "DISEASE", 187, 193], ["meningitis", "DISEASE", 198, 208], ["respiratory failure", "DISEASE", 219, 238], ["respiratory tract hemorrhage", "DISEASE", 246, 274], ["S. stercoralis", "ORGANISM", 130, 144], ["tract", "ORGANISM_SUBDIVISION", 258, 263], ["S. stercoralis", "SPECIES", 130, 144], ["S. stercoralis", "SPECIES", 130, 144], ["this study", "TEST", 16, 26], ["severe strongyloidiasis", "PROBLEM", 28, 51], ["S. stercoralis", "PROBLEM", 130, 144], ["extra gastrointestinal specimens", "PROBLEM", 150, 182], ["sepsis", "PROBLEM", 187, 193], ["meningitis", "PROBLEM", 198, 208], ["acute respiratory failure", "PROBLEM", 213, 238], ["respiratory tract hemorrhage", "PROBLEM", 246, 274], ["severe", "OBSERVATION_MODIFIER", 28, 34], ["strongyloidiasis", "OBSERVATION", 35, 51], ["stercoralis", "OBSERVATION", 133, 144], ["sepsis", "OBSERVATION", 187, 193], ["meningitis", "OBSERVATION", 198, 208], ["acute", "OBSERVATION_MODIFIER", 213, 218], ["respiratory failure", "OBSERVATION", 219, 238], ["respiratory tract", "ANATOMY", 246, 263], ["hemorrhage", "OBSERVATION", 264, 274]]], ["Severe cases were assigned to DS when larvae were found in any organ, other than those within the respiratory and gastrointestinal tracts (organs not involved in the life-cycle of S. stercoralis in humans).", [["organ", "ANATOMY", 63, 68], ["respiratory", "ANATOMY", 98, 109], ["gastrointestinal tracts", "ANATOMY", 114, 137], ["organs", "ANATOMY", 139, 145], ["respiratory and gastrointestinal tracts", "DISEASE", 98, 137], ["organ", "ORGAN", 63, 68], ["gastrointestinal tracts", "MULTI-TISSUE_STRUCTURE", 114, 137], ["organs", "ORGAN", 139, 145], ["S. stercoralis", "ORGANISM", 180, 194], ["humans", "ORGANISM", 198, 204], ["S. stercoralis", "SPECIES", 180, 194], ["humans", "SPECIES", 198, 204], ["S. stercoralis", "SPECIES", 180, 194], ["humans", "SPECIES", 198, 204], ["Severe cases", "PROBLEM", 0, 12], ["respiratory", "ANATOMY", 98, 109], ["gastrointestinal tracts", "ANATOMY", 114, 137]]], ["Medical records were reviewed to extract any relevant and related clinical features.Methods ::: BackgroundRadiological findings of chest X-ray (CXR) and chest computed tomography (CCT) taken at the onset of HS/DS were also reviewed.", [["chest X-ray", "TEST", 131, 142], ["CXR", "TEST", 144, 147], ["chest computed tomography", "TEST", 153, 178], ["CCT", "TEST", 180, 183], ["HS/DS", "TEST", 207, 212], ["chest", "ANATOMY", 131, 136], ["chest", "ANATOMY", 153, 158]]], ["If CXR or CCT was performed multiple times, an image from the date closest to onset was chosen for radiological assessment.", [["CXR", "DNA", 3, 6], ["CCT", "DNA", 10, 13], ["CXR", "TEST", 3, 6], ["CCT", "TEST", 10, 13], ["an image", "TEST", 44, 52], ["radiological assessment", "TEST", 99, 122]]], ["All radiological findings were reviewed by two respirologists, and two gastroenterologists checked for the existence of ileum gas using the same CXR.", [["ileum", "ANATOMY", 120, 125], ["ileum", "ORGAN", 120, 125], ["CXR", "PROTEIN", 145, 148], ["ileum gas", "TEST", 120, 129], ["the same CXR", "TEST", 136, 148], ["ileum", "ANATOMY", 120, 125]]], ["Patients with a simultaneous underlying pulmonary disease were excluded from the analysis of radiological findings, due to difficulties in identifying the root cause of radiological findings.Methods ::: BackgroundThe study was reviewed and approved by the Clinical Research Ethics Committee of University of the Ryukyus (H26.8\u20137-695).Patient characteristics ::: ResultsIn total, sixteen severe strongyloidiasis cases were collected: three DS and thirteen HS (Tables 1, 2).", [["pulmonary", "ANATOMY", 40, 49], ["root", "ANATOMY", 155, 159], ["pulmonary disease", "DISEASE", 40, 57], ["strongyloidiasis", "DISEASE", 394, 410], ["Patients", "ORGANISM", 0, 8], ["pulmonary", "ORGAN", 40, 49], ["root", "ORGAN", 155, 159], ["Patients", "SPECIES", 0, 8], ["Patient", "SPECIES", 334, 341], ["a simultaneous underlying pulmonary disease", "PROBLEM", 14, 57], ["the analysis", "TEST", 77, 89], ["radiological findings", "TEST", 93, 114], ["The study", "TEST", 213, 222], ["sixteen severe strongyloidiasis cases", "PROBLEM", 379, 416], ["pulmonary", "ANATOMY", 40, 49], ["disease", "OBSERVATION", 50, 57], ["root", "ANATOMY", 155, 159], ["severe", "OBSERVATION_MODIFIER", 387, 393], ["strongyloidiasis", "OBSERVATION", 394, 410]]], ["Fourteen cases had detectable S. stercoralis in extra-gastrointestinal specimens.", [["extra-gastrointestinal specimens", "ANATOMY", 48, 80], ["S. stercoralis", "DISEASE", 30, 44], ["S. stercoralis", "ORGANISM", 30, 44], ["extra-gastrointestinal specimens", "CANCER", 48, 80], ["S. stercoralis", "SPECIES", 30, 44], ["S. stercoralis", "SPECIES", 30, 44], ["Fourteen cases", "TEST", 0, 14], ["S. stercoralis in extra-gastrointestinal specimens", "PROBLEM", 30, 80], ["stercoralis", "OBSERVATION", 33, 44]]], ["Of importance, thirteen of those fourteen cases could be detected from respiratory specimen.", [["respiratory specimen", "ANATOMY", 71, 91], ["respiratory specimen", "TEST", 71, 91]]], ["Thirteen cases had gastrointestinal complications and ten had sepsis and/or meningitis.", [["gastrointestinal", "ANATOMY", 19, 35], ["gastrointestinal complications", "DISEASE", 19, 49], ["sepsis", "DISEASE", 62, 68], ["meningitis", "DISEASE", 76, 86], ["gastrointestinal", "ORGAN", 19, 35], ["gastrointestinal complications", "PROBLEM", 19, 49], ["sepsis", "PROBLEM", 62, 68], ["meningitis", "PROBLEM", 76, 86], ["gastrointestinal", "ANATOMY", 19, 35], ["complications", "OBSERVATION", 36, 49], ["sepsis", "OBSERVATION", 62, 68], ["meningitis", "OBSERVATION", 76, 86]]], ["HTLV-1 infection and hypoalbuminemia (<3.8 mg/dL) were the most common patient characteristics.", [["HTLV-1 infection", "DISEASE", 0, 16], ["hypoalbuminemia", "DISEASE", 21, 36], ["HTLV-1", "ORGANISM", 0, 6], ["patient", "ORGANISM", 71, 78], ["HTLV-1", "SPECIES", 0, 6], ["patient", "SPECIES", 71, 78], ["HTLV-1", "SPECIES", 0, 6], ["HTLV", "PROBLEM", 0, 4], ["1 infection", "PROBLEM", 5, 16], ["hypoalbuminemia", "PROBLEM", 21, 36], ["infection", "OBSERVATION", 7, 16], ["hypoalbuminemia", "OBSERVATION", 21, 36], ["most common", "OBSERVATION_MODIFIER", 59, 70]]], ["Five cases died within thirty days after diagnosis of strongyloidiasis (case fatality rate 31%).", [["strongyloidiasis", "DISEASE", 54, 70], ["strongyloidiasis", "PROBLEM", 54, 70], ["fatality rate", "TEST", 77, 90], ["strongyloidiasis", "OBSERVATION", 54, 70]]], ["Patient background and complications were compared between the five fatalities and all other cases in Table 3.", [["fatalities", "DISEASE", 68, 78], ["Patient", "SPECIES", 0, 7], ["complications", "PROBLEM", 23, 36], ["complications", "OBSERVATION", 23, 36]]], ["All fatal cases had pulmonary complications and systemic infection.", [["pulmonary", "ANATOMY", 20, 29], ["pulmonary complications", "DISEASE", 20, 43], ["systemic infection", "DISEASE", 48, 66], ["pulmonary", "ORGAN", 20, 29], ["pulmonary complications", "PROBLEM", 20, 43], ["systemic infection", "PROBLEM", 48, 66], ["fatal", "OBSERVATION_MODIFIER", 4, 9], ["pulmonary", "ANATOMY", 20, 29], ["complications", "OBSERVATION", 30, 43], ["systemic", "OBSERVATION_MODIFIER", 48, 56], ["infection", "OBSERVATION", 57, 66]]]], "PMC7205642": []}